The Oral Management of Oncology Patients Requiring Radiotherapy, Chemotherapy and / or Bone Marrow Transplantation

Clinical Guidelines

Updated 2018

The Royal College of Surgeons of England / The British Society for Disability and Oral Health
# CONTENTS

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>GUIDELINE DEVELOPMENT GROUP</td>
<td>3</td>
</tr>
<tr>
<td>INTRODUCTION</td>
<td>4</td>
</tr>
<tr>
<td>AIM OF THE GUIDELINE</td>
<td>6</td>
</tr>
<tr>
<td>TARGET GROUP</td>
<td>6</td>
</tr>
<tr>
<td>HOW TO USE THESE GUIDELINES</td>
<td>6</td>
</tr>
<tr>
<td>ORAL MANAGEMENT - OVERVIEW</td>
<td>7</td>
</tr>
<tr>
<td>1. Pathways of Care</td>
<td>7</td>
</tr>
<tr>
<td>1.1 Pre-treatment Assessment</td>
<td>7</td>
</tr>
<tr>
<td>1.2 Acute Phase of Cancer Therapy</td>
<td>7</td>
</tr>
<tr>
<td>1.3 Discharge Following Acute Phase of Cancer Therapy</td>
<td>7</td>
</tr>
<tr>
<td>2. Preventive and Clinical Regimen</td>
<td>8</td>
</tr>
<tr>
<td>2.1. Prior to cancer therapy</td>
<td>8</td>
</tr>
<tr>
<td>2.2. During cancer therapy</td>
<td>11</td>
</tr>
<tr>
<td>2.3 Following cancer therapy</td>
<td>13</td>
</tr>
<tr>
<td>ORAL MANAGEMENT - EXPLANATORY NOTES</td>
<td>17</td>
</tr>
<tr>
<td>1. Pathways of Care</td>
<td>17</td>
</tr>
<tr>
<td>1.1 Pre-treatment Assessment</td>
<td>17</td>
</tr>
<tr>
<td>1.2 Acute Phase of Cancer Therapy</td>
<td>17</td>
</tr>
<tr>
<td>1.3 Discharge Following Acute Phase of Cancer Therapy</td>
<td>18</td>
</tr>
<tr>
<td>2 Preventive and Clinical Regimen</td>
<td>19</td>
</tr>
<tr>
<td>2.1. Prior to cancer therapy</td>
<td>27</td>
</tr>
<tr>
<td>2.2. During cancer therapy</td>
<td>29</td>
</tr>
<tr>
<td>2.3 Following cancer therapy</td>
<td>35</td>
</tr>
<tr>
<td>REFERENCES</td>
<td>50</td>
</tr>
<tr>
<td>Table 1: Nursing Oral Care Guidelines</td>
<td>66</td>
</tr>
<tr>
<td>Table 2: Acute Changes during Therapy</td>
<td>69</td>
</tr>
<tr>
<td>Table 3: Chronic Changes Following Therapy</td>
<td>73</td>
</tr>
<tr>
<td>Table 4: Management Guidelines Relative to Invasive Dental Procedures</td>
<td>74</td>
</tr>
<tr>
<td>Appendix 1: Example of Search Strategy used for mucositis / pain</td>
<td>76</td>
</tr>
<tr>
<td>Appendix 2: Referral for Oral Health Care Screening</td>
<td>77</td>
</tr>
<tr>
<td>Appendix 3: Practical Oral Care</td>
<td>78</td>
</tr>
<tr>
<td>Appendix 4: Oral Assessment Guide</td>
<td>80</td>
</tr>
<tr>
<td>Appendix 5: Patient Information Leaflet</td>
<td>(i)-(ii)</td>
</tr>
</tbody>
</table>
The following colleagues were involved in the original publication of the Guideline in 1997 and/or earlier updates in 2004 and 2012:

- Jeremy Shaw
- Monty Duggal
- Janice Fiske
- Tom Nisbet
- Francesca Soldani
- Mary Burke
- Navdeep Kumar
- Debbie Lewis
- Tracey Kinsella
- Amanda O'Donnell
- Rebecca John
- Anthony Brooke

This 2018 updated Clinical Guideline aims to update the evidence base for its recommendations. It has involved stakeholder involvement from specialists in Special Care Dentistry, Restorative Dentistry, Paediatric Dentistry, Oral Surgery, and Tutor for Hygienists / Therapists. The British Society of Disability and Oral Health Research Group have also reviewed and approved the document for publication.

<table>
<thead>
<tr>
<th>Name</th>
<th>Title</th>
<th>Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>Navdeep Kumar</td>
<td>Chair of the Working Party Consultant / Honorary Senior Lecturer in Special Care Dentistry</td>
<td>University College London Hospitals NHS Foundation Trust</td>
</tr>
<tr>
<td>Mary Burke</td>
<td>Consultant in Special Care Dentistry</td>
<td>Guy’s and St Thomas’ NHS Foundation Trust</td>
</tr>
<tr>
<td>Anthony Brooke</td>
<td>Consultant in Special Care Dentistry</td>
<td>University Hospitals Bristol NHS Foundation Trust</td>
</tr>
<tr>
<td>Fabia Chan</td>
<td>Assistant Clinical Director / Specialist in Special Care Dentistry</td>
<td>Assistant Clinical Director, Kent Community Health NHS Foundation Trust</td>
</tr>
<tr>
<td>Shabnum Ali</td>
<td>Specialist in Special Care Dentistry</td>
<td>University Hospitals Bristol NHS Foundation Trust</td>
</tr>
<tr>
<td>Janine Doughty</td>
<td>Academic Clinical Fellow in Special Care Dentistry</td>
<td>University College London Hospitals NHS Foundation Trust</td>
</tr>
<tr>
<td>Hana Cho</td>
<td>Academic Clinical Fellow in Special Care Dentistry</td>
<td>University College London Hospitals NHS Foundation Trust</td>
</tr>
<tr>
<td>Stewart Barclay</td>
<td>Consultant in Restorative Dentistry</td>
<td>The Newcastle upon Tyne Hospitals NHS Foundation Trust</td>
</tr>
<tr>
<td>Lorna McCaul</td>
<td>Consultant / Honorary Clinical Senior Lecturer in Restorative Dentistry</td>
<td>Glasgow Dental Hospital and School</td>
</tr>
<tr>
<td>Jose Rodriguez</td>
<td>Specialty Trainee in Restorative Dentistry</td>
<td>University College London Hospitals NHS Foundation Trust</td>
</tr>
<tr>
<td>Elizabeth Bower</td>
<td>Tutor Dentist – Eastman Dental Hospital Education Centre</td>
<td>University College London Hospitals NHS Foundation Trust</td>
</tr>
<tr>
<td>Nikki Tanna</td>
<td>Consultant in Oral Surgery</td>
<td>University College London Hospitals NHS Foundation Trust</td>
</tr>
<tr>
<td>Edmund Bailey</td>
<td>Senior Lecturer / Honorary Consultant in Oral Surgery</td>
<td>Barts and The London School of Medicine and Dentistry</td>
</tr>
<tr>
<td>Adele Johnson</td>
<td>Consultant in Paediatric Dentistry</td>
<td>University College London Hospitals NHS Foundation Trust</td>
</tr>
<tr>
<td>Joana Monteiro</td>
<td>Consultant in Paediatric Dentistry</td>
<td>University College London Hospitals NHS Foundation Trust</td>
</tr>
</tbody>
</table>
INTRODUCTION

Cancer Statistics

Cancer is one of the leading causes of morbidity and mortality worldwide, with approximately 14 million new cases in 2012 (Ferlay et al., 2015). The number of new cases is expected to rise by about 70% over the next 2 decades. Cancer is the second leading cause of death globally, and was responsible for 8.8 million deaths in 2015. Globally, nearly 1 in 6 deaths is due to cancer, although in low- and middle-income countries, this figure increases to 70% of deaths.

Tobacco use is the most important risk factor for cancer and is responsible for approximately 22% of cancer deaths (GBD Collaborators, 2016). Cancer causing infections, such as hepatitis and human papilloma virus (HPV), are responsible for up to 25% of cancer cases in low- and middle-income countries (Plummer et al., 2016). In 2015, more than 90% of high-income countries reported treatment services are available compared to less than 30% of low-income countries.

In the United Kingdom, there were over 357,000 new cases of cancer in 2014. This equates to 980 cases diagnosed every day, with one person diagnosed every two minutes with cancer (Cancer Research UK, 2017). In 2014, there were 181,000 cases of males and 176,000 cases of females diagnosed with cancer. Since the early 1990s, incidence rates for all cancers combined have increased by 12% in the UK. The increase is more pronounced in females (16%), than in males (4%). Almost half of cancers are diagnosed at a late stage in England (2014) and Northern Ireland (2010-2014). Incidence rates for all cancers combined are projected to rise by 2% in the UK between 2014 and 2035, to 742 cases per 100,000 people by 2035.

Conversely, the outlook following treatment for malignant disease, has improved in the last two decades since the 1995 Calman-Hine report which outlined radical reform of the UK’s cancer services with the aim of improving outcomes and reducing inequalities in NHS cancer care (Department of Health, 1995). Its main recommendation was to concentrate care into the hands of site-specialist, multi-disciplinary teams – dental care is an essential component of these teams.

Importance of Integrated Oral Care

Complications in the oral cavity commonly arise as a result of malignancy and/or the undesirable effects of its treatment (Brennan et al., 2010) (Shaw et al., 2000). The prevalence, extent, severity and longevity of the complications depend on the regime of cancer therapy regime and its intensity (National Cancer Institute, 2016).

Complications may include profound functional and sensory changes to the oral mucosa, in addition to an increased susceptibility to dental caries and periodontal disease (National
Cancer Institute, 2016) (Sroussi et al., 2017). These may impact directly on cancer therapy resulting in the need to pause treatment, but also have a significant impact on the longevity and quality of life during and after cancer therapy (Gandhi et al., 2017).

Adults with malignant disease, in common with the general population will increasingly keep their natural teeth to a greater age but they are likely to have more untreated dental disease. Children with cancer may also have untreated dental caries and, since many are under five years of age, a significant proportion may not have previously had a dental examination (Rosales et al., 2009).

Following major head and neck surgery, around 78% of patients have been reported to experience severe difficulties with mastication, which may have implications for normal social adaptation. At least one third of head and neck survivors had moderate and severe level of distress. Seventy-four percent reported at least one unmet need, the most common being oral and eating problems (Kraaijenga et al., 2015) (Wells et al., 2015) (Wilberg et al., 2014) (Kamstra et al., 2013) (Roe et al., 2012). Haemato-oncology patients equally experience poorer quality of life when measured using the parameters of oral functional limitation, physical pain and physical disability (Tinoco-Araujo et al., 2015) (Mays et al., 2013). These difficulties can be improved by carefully planned oral and dental assessment, early intervention and reconstruction (Butterworth et al., 2016).

In summary, dentists are increasingly likely to find that they have children and adults in their care who may present before or after cancer treatment requiring dental assessment and / or urgent dental care. The patient’s oral care and function are important contributors to post-treatment social adaptation and life quality (Kolokythas, 2010) (Shavi et al., 2015) (Thani and Bumb, 2014). Appropriate preventive regimens, timely oral care and improved dental services can minimise complications and improve quality of life (Bennadi and Reddy, 2013).

These guidelines provide an overview of the current recommendations in relation to dental care for all patients undergoing cancer therapy. The reader is advised to also review complimentary guidelines specific for patients receiving surgical and non-Surgical treatment for Head and Neck Cancer produced by Restorative Dentistry UK in 2016 (RD-UK, 2016).

**Dr. Navdeep Kumar**  
Chair of the Guideline Development / Update Group
AIM OF THE GUIDELINE

To improve the quality of life for patients with malignant disease, who are receiving cancer therapy that has implications for oral comfort and function, by promoting consistent, evidence-based high standards of oral care through a co-ordinated team approach.

TARGET GROUP

Cancer therapy that may result in oral complications includes:
- Chemotherapy
- Radiotherapy to the head and neck
- Surgery to the head and neck
- Bone marrow transplantation – involves chemotherapy +/- total body irradiation

HOW TO USE THESE GUIDELINES

These guidelines provide an overview of the oral management of both children and adults receiving radiotherapy, chemotherapy, surgery or a combination of these modalities.

The recommendations must be seen as a contribution to total patient care and as such should always be implemented in conjunction with the care priorities agreed with the oncology team.

An Overview of the recommendations with regards to oral management is summarised at the beginning of the document. This is followed by an Explanatory Notes section that provides the reader with further information where available.

A list of References accessed to support the recommendations is provided. There are also Tables, Appendices and a template for a Patient Information Leaflet at the end of the document.

REFERENCES / SEARCH STRATEGY

The search strategy used by the authors involved a review of the literature. Agreed search terms from the following databases were used to identify publications relevant to this cohort of patients:
- Cochrane Database of Systematic Reviews (CDSR)
- Database of Abstracts of Reviews of Effects (DARE)
- Cochrane Central Register of Controlled Trials (CENTRAL)
- Health Technology Assessment (HTA) database
- MEDLINE
- EMBASE
- NHS Evidence > Filter > Guidelines

An example of the search strategy used for mucositis is included in Appendix 1. The Oxford Centre for Evidence-based Medicine Level of Evidence (2009) was used to grade the level of evidence. The GRADE (Grading of Recommendations Assessment, Development and Evaluation) method was used to systematically assess the strengths and limitations of the evidence base.
**ORAL MANAGEMENT - OVERVIEW**

## 1. Pathways of Care

A clear pathway of care is necessary to prevent or minimise oral complications. It is recognised that not all cancer centres have a linked multi-disciplinary dental team and hygienist support. However the pathway outlined represents the evidence-based ideal pathway to ensure optimal outcomes.

### 1.1 Pre-treatment Assessment

1.1.1 Every relevant oncology protocol should include an early pre-treatment oral assessment.

1.1.2 A permanent member of the oncology team is responsible for arranging the oral assessment using a standardised referral form (Appendix 2).

1.1.3 A designated permanent member of dental team is responsible for organising oral care.

1.1.4 Dentally, the cancer patient will require multi-specialty, multidisciplinary and collaborative care approach to achieve best oral outcomes and an efficiently delivered oral care pathway.

### 1.2 Acute Phase of Cancer Therapy

1.2.1 The oncology team must include a trained dental professional who is responsible for the patients’ oral care.

1.2.2 The dental hygienist is responsible to the designated member of dental team.

1.2.3 The designated member of dental team is responsible for arranging or carrying out any urgent dental treatment required.

1.2.4 Nursing guidelines for oral assessment and routine oral care should be followed (Appendices 3-4, Table 1).

### 1.3 Discharge Following Acute Phase of Cancer Therapy

1.3.1 The oncology patient discharge protocol includes a procedure for ensuring continuing oral care.

1.3.2 The designated member of dental team is responsible for organising and monitoring appropriate continuation of oral care.

1.3.3 Following the receipt of a bone marrow transplant and subsequent discharge home from hospital, children are reviewed to continually monitor the oral condition.

1.3.4 There is an agreed patient-specific minimum period of oral health monitoring post-treatment.

1.3.5 Children are monitored during their period of growth and development.
2. Preventive and Clinical Regimen

2.1. PRIOR TO CANCER THERAPY

2.1.1. Importance of Integrated Care:

Oral care should be seen as a contribution to total patient care and implemented in conjunction with the care priorities agreed with the oncology team (Shaw et al., 2000).

2.1.2. Oral / Dental Assessment:

Prior to commencement of cancer therapy, an oral / dental assessment including radiographs, must be undertaken (Elad et al., 2015). The specific aims are to:

- Identify existing oral disease and potential risk of oral disease.
- Remove infectious dental / oral foci before the start of cancer therapy.
- Prepare the patient for expected side effects of cancer therapy.
- Establish an adequate standard of oral hygiene to meet the increasing challenges during cancer therapy.
- Develop a plan for maintaining oral hygiene, providing preventive care, completing oral rehabilitation and follow-up.
- Establish the necessary multidisciplinary collaboration within the cancer centre to reduce / alleviate oral symptoms and sequelae before, during and after cancer therapy.

Each centre should have a multidisciplinary team to accomplish these goals; the exact methods used may vary between cancer centres (Schiodt and Hermund, 2002). Specific recommendations apply to the assessment of paediatric patients (Public Health England, 2017) (Abdullah, 2014) (SDCEP, 2010).

2.1.3. Advice Regarding Potential Side-Effects:

Chemotherapy and radiotherapy can cause adverse short- and long-term oral side effects (Butterworth et al., 2016). Realistic simple preventive advice should be given, emphasising its value in maintaining oral comfort during therapy and reducing complications (Tables 2-3; Appendix 5 – Patient Information Leaflet)
2.1.4. Oral Hygiene instructions: 

Detailed oral hygiene instruction is provided.

2.1.5. Dietary Advice: 

It is recommended that dietary advice is given in liaison with the dietitian and presented with the emphasis upon ensuring oral comfort during therapy.

2.1.6. Chlorhexidine: 

If gingival disease is diagnosed, oral hygiene practices can be supplemented with the use of an alcohol-free chlorhexidine mouthwash or dental gel.

2.1.7. Periodontal treatment: 

Professional debridement of plaque and calculus deposits should be undertaken to stabilise periodontal disease.

2.1.8. Dental caries: 

Where possible carious teeth should be definitively restored or stabilised with appropriate restorations.

2.1.9. Removal of trauma: 

All sharp teeth and restorations are suitably adjusted and polished.

2.1.10. Impressions: 

Impressions of the mouth are taken for study casts to construct applicator trays and, where appropriate, for intra-oral radiation stents and obturator planning.

2.1.11. Dentures / obturators: 

The patient is counselled about denture wear during cancer therapy. If a removable prosthesis is worn, it is important to ensure that it is clean and well adapted to the tissue. The patient should be instructed not to wear the prosthesis during cancer therapy, if possible; or at least, not to wear it at night (National Institute of Dental and Craniofacial Research, 2015).

2.1.12. Dental Extractions: 

Wherever possible, teeth with a dubious prognosis are removed no less than
ten days prior to commencement of cancer therapy (Clayman, 1997).

2.1.13. **Antibiotic prophylaxis / haematological support:**

Antibiotic prophylaxis prior to invasive oral procedure may be warranted in the context of neutropenia (neutrophils less than 2000/mm3) although liaison with the oncologist should take place and clinical judgement exercised. Haematological support may also be required (Table 4).

2.1.14. **Orthodontics:**

Orthodontic treatment should be discontinued and fixed appliances removed (Sheller and Williams, 1996).

### KEY RECOMMENDATION

Wherever possible, teeth with a dubious prognosis are removed no less than ten days prior to commencement of cancer therapy (Weak recommendation, very low quality evidence).
2.2. DURING CANCER THERAPY

2.2.1. Hygienist Support:

The patient should receive appropriate support from a dental hygienist or therapist.

2.2.2. Oral / Denture Hygiene:

A high standard of oral hygiene is encouraged, including denture hygiene.

2.2.3. Antibacterial Mouthwash:

The use of an alcohol-free chlorhexidine mouthwash is recommended if toothbrushing is likely to be inadequate for plaque removal; it can be used in addition or as a short-term alternative to tooth brushing.

2.2.4. Dental Caries Risk:

Those patients receiving radiotherapy to the head and neck region, or total body irradiation prior to bone marrow transplantation are at higher risk of dental caries and should receive dietary advice and fluoride preparations appropriate to their age (Hong et al., 2010) (Gawade et al., 2015) (Gupta et al., 2015).

2.2.5. Viral Infections:

Children and adults receiving bone marrow transplants often receive aciclovir as a prophylaxis if there is a high risk of viral infections. This is usually prescribed by the oncology team (Sanderr et al., 2015) (Ullmann et al., 2016).

2.2.6. Fungal Infections:

Antifungal medication is used following detection of oral candida (Pappas et al., 2016). For children, this may be used routinely as a prophylaxis in some cancer centres.

2.2.7. Mucositis:

Regular assessment of the mouth should be undertaken to record the presence and severity of mucositis. Every effort is made to reduce the severity and control oral discomfort.
2.2.8. Xerostomia:

Every effort is made to reduce the effect of the xerostomia for quality of life and prevention of oral disease.

2.2.9. Dentures / Obturators:

Patients are advised that removable prostheses may become difficult to wear and may need to be left out. If there is any discomfort they should be examined by a member of the dental team and adjusted to ensure they are atraumatic.

2.2.10. Foam swabs / Oral Cleanser / Gauze:

If the mouth is too painful for cleaning with a soft toothbrush, the tissues can be cleaned with oral sponges, an oral cleanser stick (e.g. MC3), or gauze moistened with alcohol-free chlorhexidine mouthwash. Of note, some units have discontinued the use of oral sponges due to the risk of inhalation if the sponge becomes detached.

2.2.11. Dietary Advice:

Certain food, drinks and mouthwashes, which irritate the oral mucosa, should be avoided to maintain oral comfort.

2.2.12. Dental Treatment:

Elective dental treatment is avoided wherever possible during cancer therapy.

2.2.13. Obturators:

If the patient is having surgical resection to the maxilla / mid-face, obturators can be planned and fitted peri-operatively.

---

**KEY RECOMMENDATION**

Those patients receiving radiotherapy to the head and neck region, or total body irradiation prior to bone marrow transplantation are at higher risk of dental caries and should receive dietary advice and fluoride preparations appropriate to their age. (Strong recommendation, very low quality of evidence).
2.3 FOLLOWING CANCER THERAPY

2.3.1 Monitoring:

Susceptibility to dental disease can be lifelong following cancer therapy therefore patients must be monitored closely.

2.3.2 Dental Caries Risk:

The risk of dental caries following cancer therapy will depend on the type of treatment the patient has received, and changes in oral health-related behaviours as a consequence of the treatment. Individualised oral health prevention and monitoring programme should be established for each patient, with frequent recall intervals based on the patient's oral disease risk assessment.

2.3.3 Gingival / Periodontal Risk:

Bone marrow transplant patients on ciclosporin may need more frequent hygienist support if gingival hyperplasia is a side effect. In the event of uncontrolled periodontal disease, vigorous treatment is initiated. This may involve identification of atypical pathogens.

2.3.4 Preventive Advice and Fluoride supplementation:

Dietary analysis and advice should aim to encourage a healthy balanced diet and reduce the amount and frequency of sugars and acids. Close liaison with the patient's dietitian is necessary. The dental hygienist should provide tailored oral hygiene support. The use of fluoride preparations is recommended.

2.3.5 Xerostomia:

Salivary stimulants and saliva replacement products are outlined in section 2.2.8 explanatory notes.

2.3.6 Smoking Cessation:

Smoking and alcohol cessation support should be ongoing. Support to stop the use of smokeless tobacco and betel quid should also continue.

2.3.7 Abnormal Blood counts:

Patients on maintenance chemotherapy or with persistent haemato-oncology
disease may need blood tests pre-operatively if invasive treatment is planned. Bleeding and infection risk may be of concern for invasive procedures and require close liaison with the oncology team.

2.3.8 Herpes Labialis:

Herpes labialis can be a chronic problem and requires timely management. Topical aciclovir may be effective.

2.3.9 Limited Mouth Opening:

The team should be vigilant that this is not due to a local recurrence, metastatic lesions in the head and neck region and/or a second malignant lesion. If this has been excluded, jaw exercises, stacked tongue spatulas and jaw opening devices can be used. Starting therapy early and compliance with exercises improves treatment outcome.

2.3.10 Growth and Development:

This should be closely monitored. Survivors of childhood cancer are at risk of dental developmental abnormalities. Microdontia, tooth agenesis and xerostomia may present as delayed side effects of cancer therapy. Early specialist involvement is essential to ensure good outcomes.

2.3.11 Orthodontics:

The decision to embark upon orthodontic treatment must be taken carefully. Challenges include increased dental caries susceptibility, root stunting, risk of osteonecrosis following orthodontic extractions in patients who have received anti-resorptive agents, and the inhibiting effect of bisphosphonates on orthodontic tooth movement.

2.3.12 Restorations:

Restorations are kept simple ensuring acceptable aesthetics and function.

2.3.13 Dental Extractions:

The risk of osteoradionecrosis and/or medication-related osteonecrosis of the jaw should be considered. Dental extractions should be avoided wherever possible in patients at risk of developing these complications. If essential, they must be performed with appropriate precautions.
2.3.14 Dentures:

Dentures should be avoided wherever possible. Removable prostheses are left out at night. Oral lubricants / artificial saliva may be applied to the fit surface of the denture to improve comfort and retention when xerostomia is present. Acidic saliva substitutes (e.g. Glandosane) should be used for edentate patients only. Antifungals are used if a candidal infection is diagnosed. These can be applied directly to the fit surface of the denture or incorporated into the soft lining. Microwave disinfection may also be used for maxillary complete dentures. Appliance wear is discontinued if the mouth becomes painful and advice must be sought.

2.3.15 Dental Implants:

Implant stabilisation of prostheses and obturators may be feasible in some patients.

2.3.16 Obturators:

Unlike dentures, obturators should not be left out at night for the six months following treatment. They must be reviewed regularly by the restorative dental team, as frequent attention with adjustment or remake may be required.

2.3.17 Osteoradionecrosis (ORN):

Establish the clinical diagnosis of ORN and its stage, ensuring that the bony changes are not due to malignancy. Following a diagnosis of ORN it is recommended that oral trauma is minimised, and a high standard of oral hygiene is established. Local measures are employed to relieve symptoms including topical / systemic analgesia. Therapeutic use of antioxidant medications may be of significant benefit in ORN lesions identified early. High dose systemic antibiotics are prescribed if there are symptoms of persistent infection. Localised surgical excision of exposed necrotic bone with primary mucosal closure may become necessary. In some cases, the use of hyperbaric oxygen therapy (HBOT) may be a beneficial adjunct to surgical interventions but should only be used as part of a clinical trial. In advanced chronic cases, the extent of involvement of bone necrosis must be established followed by radical ablative surgery to remove necrotic bone.

2.3.18 Medication related Osteonecrosis of the Jaw (MRONJ):

MRONJ, although relatively rare, can occur as a result of medications commonly used in the treatment of some cancers. Patients should receive verbal and written information of the risks. Various preventive and treatment strategies have been proposed but the evidence regarding their efficacy is currently poor (SDCEP, 2017).
2.3.19 Discharge:

The majority of patients can be discharged to the primary care dental team for long-term review. More frequent follow up is required.

**KEY RECOMMENDATION**

The risk of osteoradionecrosis and / or medication-related osteonecrosis of the jaw should be considered. Dental extractions should be avoided wherever possible in patients at risk of developing these complications. If essential, they must be performed with appropriate precautions. (Strong recommendation, moderate quality of evidence)
These explanatory notes refer to the paragraph numbers indicated in the Pathways of Care and the Preventive and Clinical Regimen (see above).

### 1. Pathways of Care

#### 1.1 Pre-treatment Assessment

**1.1.1 There is no universally accepted pre-cancer therapy dental protocol because of the lack of clinical trials evaluating the efficacy of a specific protocol.**

- Currently, many of the dental protocols proposed are related to specific cancers only, such as head and neck cancer where the mouth may receive significant irradiation (Nekhlyudov et al., 2017) (Butterworth et al., 2016) (Cocks et al., 2016) (Jawad et al., 2015) (Patel et al., 2015).

- A systematic review of the literature revealed only limited articles on oral care protocols prior to cancer therapy (Hong et al., 2018) (Hong et al., 2010) (Epstein et al., 2014).

- While there are no universally accepted dental protocols, all papers emphasize the importance of optimisation of oral health prior to, during and post cancer therapy. Effective oral management can reduce interruption of cancer treatment and improve quality of life (Talwar et al., 2016) (Rathod et al., 2015) (Wells et al., 2015) (Shiraz et al., 2014) (Kelly, et al., 2013). Additionally, all authors emphasise the importance of good communication between the oncology multidisciplinary team and the dental team throughout the patient journey.

- An appropriately experienced dental team is often required to perform dental care for oncology patients (Epstein et al., 2009).

- Time must be made available during the pre-treatment phase for a dental assessment and necessary emergency care, especially when radiotherapy is planned and for those where dental treatment may be contraindicated once oncology intervention commences (Butterworth et al., 2016) (Epstein et al., 2009) (Elad et al., 2003) (Raut et al., 2001).

- Ideally, a comprehensive oral evaluation should take place as soon as practicable after cancer diagnosis to allow maximum time for dental treatment and subsequent healing.

- In the case of patients with head and neck cancer, it is important to undertake the oral assessment when the cancer treatment plan is available. This will allow the dental team to be aware of areas in the mandible and maxilla may be involved in...
surgery and / or radiotherapy.

- It has been suggested that dental teams should assess the patient approximately one month before cancer treatment begins in order to allow urgent dental treatment to be arranged and to subsequently ensure adequate time for recovery from any required invasive dental procedures (see section 2.12) (Bos-den Braber et al., 2015) (Abdullah, 2014) (McCaul, 2012) (Shaw et al., 2000).

1.1.3 Designated dental member of staff:

- The member of dental staff responsible for organising oral care will need to ensure that dental treatment is provided rapidly, taking into consideration the patient's existing continuing care arrangements.

- Depending on the specialty availability and the urgency, treatment may be provided either within the hospital service, the community dental service or the general dental service (Jawad et al., 2015).

- Where there is any doubt about rapid efficient treatment, or the patient’s general health status dictates, dental care should be undertaken within the specialist centre.

- Medical consultation is indicated before invasive procedures (Tsuji et al., 2015) (Yamagata et al., 2011) (Yamagata et al., 2006).

1.1.4 Multidisciplinary care:

- Dentally the cancer patient will require a multispecialty, multidisciplinary and collaborative care approach to achieve best oral outcomes and an efficient oral care pathway (Nekhlyudov et al., 2017) (Epstein et al., 2014).

1.2 Acute phase of cancer therapy

1.2.2 Oral care:

Oral care must be seen as an integral part of patient care. A dental hygienist should be part of the team providing the patient's oral care during therapy (Michele and Lloid, 2016) (Ray-Chaudhuri et al., 2013). However, dental hygienists may be difficult to recruit. In such circumstances, an appropriately trained member of nursing staff can undertake this role (Dempsey et al., 2016) (Jawad et al., 2015).

1.2.4 Nursing guidelines:

It is particularly important for specific nursing guidelines to be available and utilised for oral care in the period leading up to and following bone marrow transplantation. (Appendix 2).
1.3 Discharge Following Acute Phase of Cancer Therapy

1.3.1 Monitoring:

In the absence of recurrent disease oral health monitoring should at least be equivalent to the period of monitoring by the oncology team (Nekhlyudov et al., 2017) (Roman et al., 2016) (Majhail et al., 2012). Recall should be three-monthly to start with and the period should be adjusted dependent on the patient risk factors (NICE, 2004). Patients with unstable oral health will require more frequent monitoring. In circumstances of stable oral health, monitoring should be agreed with the primary care dentist with an appropriate procedure for urgent re-referral. In the case of patients with head and neck cancer, they should be seen as soon as possible after completion of radiotherapy and the frequency of follow up in the immediate post treatment phase will also depend on severity of side-effects.

1.3.2 Children who have received bone marrow transplants should have a strict follow-up for preventive oral care at three monthly intervals.
2 Preventive and Clinical Regimen

<table>
<thead>
<tr>
<th>2.1. PRIOR TO CANCER THERAPY</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>2.1.1. Importance of Integrated Oral Care:</strong></td>
</tr>
<tr>
<td>When presented with a diagnosis of cancer a patient will be unlikely to consider the oral implications as a high priority. However, it is important that patients and carers are counselled about oral care procedures, diet and the oral implications of the proposed treatment (Shaw <em>et al.</em>, 2000).</td>
</tr>
<tr>
<td><strong>2.1.2. Oral / Dental Assessment:</strong></td>
</tr>
<tr>
<td><strong>Adults:</strong></td>
</tr>
<tr>
<td>- The pre-treatment evaluation should include a thorough examination of hard and soft tissues, as well as appropriate radiographs to detect possible sources of infection and pathology (Butterworth <em>et al.</em>, 2016) (Epstein <em>et al.</em>, 2014).</td>
</tr>
<tr>
<td>- Those patients who are to undergo surgery and / or radiotherapy to the jawbone, should be assessed by the restorative dentist who works with the surgeon in the multidisciplinary team (Butterworth <em>et al.</em>, 2016) (Michele and Lloid, 2016) (Abdullah, 2014) (McCaul, 2012) (Westbrook <em>et al.</em>, 2003).</td>
</tr>
<tr>
<td>- Often, there is insufficient time to provide complex dental care before cancer treatment commences.</td>
</tr>
<tr>
<td>- Oral problems that already exist, such as periodontitis, caries, failing restorative work (such as leaking crowns or fillings), and ill-fitting dentures may increase the risk of infection (Tomblyn <em>et al.</em>, 2009).</td>
</tr>
<tr>
<td>- Elimination of dental disease by judicious restorative dentistry, periodontal treatments and extraction of teeth with a questionable prognosis are important preventive strategies to avoid future dental extractions, an important risk factor for osteonecrosis of the jaw (Patel <em>et al.</em>, 2015) (Ertas <em>et al.</em>, 2014 ) (NICE, 2012) (Peterson <em>et al.</em>, 2010) (Stoopler <em>et al.</em>, 2007).</td>
</tr>
<tr>
<td>- Guidelines for dental extractions, endodontic management, and related interventions can be used as appropriate (SDCEP, 2017) (National Cancer Institute, 2016) (Stoopler <em>et al.</em>, 2007).</td>
</tr>
<tr>
<td>- The likelihood that a tooth will require extraction within the next few years must be assessed. Additionally, not all patients are well motivated, and in such cases, retaining teeth may lead to complications in the future (Patel <em>et al.</em>, 2015) (Elad <em>et al.</em>, 2003). This is particularly important for the patient</td>
</tr>
</tbody>
</table>
who may receive oral radiotherapy or high dose intravenous bisphosphonates for cancer treatment (Stoopler et al., 2007).

- The advice needs to be set within the overall framework of care set by the oncologist and their support staff.

**Children:**

The following specific recommendations have been made (Public Health England, 2017) (Abdullah, 2014) (SDCEP, 2010):

**Access to Dental Care**

- All children diagnosed with cancer should have access to or preferably be registered with an NHS general dental practitioner, Community Dental Service or Hospital based Paediatric Dental Service.

- Registration should be maintained during and following cancer treatment.

- The routine dental care provider in community or general dental practice should be notified of the cancer diagnosis and arrangements for care during cancer treatment as directed by the hospital dental team, in a shared care arrangement.

- For paediatric dental units working with a cancer centre, there should be a mechanism of notification for new patients.

- All children should undergo a dental assessment, including radiographs at the time of diagnosis, if possible before cancer treatment commences. If this is not possible it should be as soon as it is practically possible.

- If invasive dental treatment is required, this should be undertaken either by a consultant or a specialist in paediatric dentistry as appropriate.

- If there is no paediatric dental unit liaising with the cancer centre, there should be clear communication between the cancer centre and routine care provider.

- Appropriate training in oral assessment should be available for the oncology nurses within the cancer centre, ideally in collaboration with a member of the dental team.

**2.1.3. Advice Regarding Potential Side-Effects:**

Patient education is an integral part of the pre-treatment evaluation and should include a discussion of potential oral complications (Abdullah, 2014) (Mays et al., 2013) (Westbrook et al., 2003).
2.1.4. Oral Hygiene Instruction:

**Adults:**

- It is very important that the dental team impress on the patient that optimal oral hygiene during treatment, adequate nutrition, and avoiding tobacco and alcohol can prevent or minimise oral complications and reduce recurrence / further cancers (Brand et al., 2009) (Goldman, 2006). Patients should understand that good oral care during cancer treatment contributes to its success (Michele and Lloid, 2016) (Critchlow et al., 2014) (Epstein et al., 2014).

- To ensure that the patient fully understands what is required, detailed instructions should be provided on specific oral care practices, such as how and when to brush and floss, how to recognise signs of complications, and other instructions appropriate for the individual.

**Children:**

- Oral hygiene advice should be given to children and parents prior to commencing cancer treatment and this should be provided both verbally and in writing.

- Oral hygiene advice should be given by a designated member of the dental team or, in the absence of a dentally trained individual, a member of the medical or nursing team who has received appropriate training.

- Advice should be to brush at least twice a day – last thing at night and at least one other occasion.

- Children from 0 to 10 years should use fluoridated toothpaste containing 1350-1500ppm fluoride. Up to 6 years old children should use only a smear or pea sized amount of toothpaste.

- Reinforce the importance of spitting and not rinsing after toothbrushing.

- From 8 years of age and above, children should use a fluoride mouth rinse daily (0.05% NaF) at a different time to brushing.

- Children with active caries should use a prescribed 2800ppm fluoridated toothpaste (if 10 years or above) or prescribed 5000ppm fluoridated toothpaste (if 16 years old or above).

- The toothbrush should be for the sole use of the child and changed on a three-monthly basis, or when bristles splay, if earlier. A child’s toothbrush should be changed following an oral infective episode.

- If the child has a sore mouth a soft brush with a small head should be used.
- Children need to be helped or supervised by an adult until at least 7 years of age; parents/carers should be instructed on how to brush their child’s teeth.

- For babies without teeth, parents/carers should be instructed on how to clean the mouth with oral sponges if available. The sponge should be moistened with water. Some units have discontinued the use of oral sponges due to the risk of inhalation if the sponge becomes detached. In this situation, a soft brush or gauze may be used.

- For children where it is not possible to brush teeth, parents / carers should be instructed on how to clean the mouth with oral sponges / gauze, as a temporary measure. The sponge / gauze should be moistened with water or an antimicrobial agent such as diluted alcohol-free chlorhexidine may be used.

- Additional aids such as flossing may be advised for motivated parents / carers.

- The need to restrict sugary food and drink to meal times only 3-4 occasions in a day should be discussed in accordance with the dietitian’s instructions.

- Give examples of sugar-free snacks, warn of hidden sugars in foods and highlight the high acid content of some drinks.

- If possible, sugar free medication should be considered, if available, in order to minimise cariogenic effects.

2.1.5. Dietary Advice:

- Since many children and some adults need a frequent high calorific intake during therapy, this usually translates into an increased and frequent intake of refined carbohydrate (sugar), which, if sustained, can lead to dental caries.

- It is important to ensure that dietary advice pre-cancer therapy does not conflict with the advice given by the dietician. The focus is on the patient maintaining their weight and receiving adequate nutrition.

- It may be possible to utilise alternative strategies such as the use of straws when consuming sweet drinks.

- Information at this stage must be supported by an appropriately designed information leaflet.

2.1.6. Chlorhexidine:

The use of an aqueous alcohol-free chlorhexidine mouthwash, dental gel or
spray will contribute to the treatment of gingival disease in combination with improved oral hygiene practices. Use either a mouthwash or dental gel twice daily for at least one week prior to commencing treatment. The following are appropriate:

- 10ml of 0.2% aqueous alcohol-free chlorhexidine gluconate mouthwash or dental gel
- 18ml of 0.12% aqueous chlorhexidine gluconate solution

In children chlorhexidine is rarely used unless toothbrushing cannot be performed. There is often poor compliance because of the taste.

2.1.7. Periodontal Treatment:

A thorough debridement of plaque and calculus should decrease gingival inflammation and has the potential to decrease the severity of oral mucositis (Saito et al., 2014). The oncology team should be consulted where blood counts may be altered in relation to haemato-oncological disease.

2.1.8. Dental Decay:

Where time permits it is preferable to restore teeth with a permanent restorative material. When time is limited, glass ionomer cements or preferably resin modified glass ionomer cements make an effective provisional restoration.

2.1.9. Removal of Trauma:

Sharp teeth or restorations can be particularly uncomfortable during the period of mucositis. They can contribute to soft tissue damage, ulceration, mucositis and attendant discomfort. They should be appropriately adjusted.

2.1.10. Impressions:

- Impressions may be required for the construction of intraoral stents when radiotherapy is used for the treatment of head and neck cancers. Stents can be effective in decreasing doses to healthy structures and delaying the emergence of mucositis (Doi et al 2017)
- In cases with mandibular resection (and / or reconstruction) resulting in edentulous areas, it may be possible to restore with conventional full or partial dentures.
- Pre-operative decision making in conjunction with the surgeon can optimise
hard and soft tissue contours to aid prosthesis stability and retention.
- Study casts should be used for obturator planning in liaison with the surgical team.
- Where possible a maximal number of well-maintained natural teeth of reasonable prognosis should be retained to assist with support and retention.
- However, obturators will often require a combination of tissue and/or tooth-borne support and can also be retained by osseointegrated dental and/or zygomatic implants.
- If multiple casts are required, applicator trays can always be made on duplicate casts to avoid repeated impressions.
- The applicator trays are used for fluoride or chlorhexidine gel delivery later in the management process.

2.1.11. Dentures / Obturators:

- Dentures or obturators are uncomfortable during the period of mucositis.
- The patient may wish not to wear dentures during this time.
- Those who discontinue the use of their dentures often experience problems with denture stability when they return to them, probably as a result of adaptation loss. They should be counselled in advance so that they can make an informed choice and relatives can be prepared for any change in appearance.
- Obturators must be worn since wound contraction can occur within hours of removal. If painful, they must be examined by a member of the dental team.

2.1.12. Dental Extractions:

- The implications of any dental extractions subsequent to radiotherapy must be sensitively explained to the patient.
- Teeth in direct association with the tumour, in the direct path of the radiation beam, or teeth with doubtful prognosis (deep caries, deep periodontal pockets, non-vital teeth) should be extracted as soon as possible before radiotherapy and high dose intravenous bisphosphonate treatment (McCaul, 2012) (Stoopler et al., 2007) (SDCEP, 2017).
- It should be borne in mind that permanent teeth with non-symptomatic periapical lesions are rarely exacerbated by cancer therapy. Judgement needs to be made on overall prognosis.
- Children should have mobile and teeth of questionable prognosis removed.
Pulp therapy in primary teeth is contra-indicated for immunocompromised children (Rodd et al., 2006).

- Teeth should be removed with a minimum of trauma
- Primary closure has been advocated but the evidence supporting this approach is not conclusive (Elyas et al., 2013).
- Ideally allow three weeks between dental extraction and commencement of radiotherapy, although this is not always practicable. This is to allow for maximal healing time (McCaul, 2012) (Stoopler et al., 2007).
- Some authors have proposed a minimum two weeks healing period and the patient should be reviewed to ensure mucosal healing (Butterworth et al., 2016) (Critchlow et al., 2014) (Yamagata et al., 2011) (Yamagata et al., 2006). Ten days should be considered a minimum period (Clayman, 1997).
- Where possible, children due to undergo an autologous stem cell transplant who are not compliant with dental treatment under local anaesthesia, may have any appropriate teeth removed at the time as their bone marrow harvest general anaesthetic.
- Patients are particularly at risk of ORN when tooth extractions are undertaken both immediately before and after radiotherapy.

2.1.13. Antibiotic Prophylaxis:

- Antibiotic prophylaxis regimens prior to invasive oral procedures in neutropaenic patients frequently use the current American Heart Association (AHA) protocol for infective endocarditis and oral procedures (Nishimura et al., 2017). It is important to discuss the proposed plan regarding antibiotics with the oncologist.

2.1.14. Orthodontics:

Children undergoing orthodontic therapy should have their orthodontic appliance removed and treatment discontinued until two years after completion of cancer therapy (Sheller and Williams, 1996).
2.2. DURING CANCER THERAPY

2.2.1. Hygienist / Nursing Support:

The period of mucositis is extremely unpleasant and close support from a dental hygienist or appropriately trained dental team member / general nurse is beneficial. The patient should be constantly reassured during this acute phase about the limited period of this side effect of treatment.

2.2.2. Oral / Denture Hygiene:

Normal daily toothbrushing by the patient, carer or parent, with a powered or manual medium brush should be undertaken, with supplemental use of floss or interdental brushes (Robinson et al., 2005) (Public Health England, 2017).

- If brushing becomes very painful a soft brush (e.g. TePe Special Care Toothbrush) can be substituted, particularly for those patients receiving chemotherapy where their platelet levels are low.

- However, it should be noted that soft brushes are not as effective for plaque control and this is of particular concern for patients with head and neck cancer who may have profound changes in the oral cavity, including widespread mucositis and xerostomia. In these patients, a single tufted or children’s toothbrush may be preferable.

- Normal toothbrushing should be resumed at the earliest opportunity

Dentures should be rinsed after meals and cleaned at least once daily by brushing with a toothbrush and soaked in chlorhexidine mouthwash overnight. An alternative is dilute sodium hypochlorite solution (Milton’s diluted 1 in 80) provided there are no metal components. Dentures should not be worn at night.

2.2.3. Antibacterial Mouthwash

If brushing is difficult, for example after surgery, chlorhexidine mouthwash may be used in addition. It is an effective antibacterial and is available in concentrations 0.12-0.2% mouthwash. It is important to use the alcohol free preparations. 10ml should be rinsed round the mouth for 1 minute then spat out, twice daily. For children, it may be applied with gauze or sponges, as mouth rinsing may be difficult. Thirty minutes should be allowed between use of chlorhexidine and toothbrushing. The 0.2% concentration may be diluted 1:1 with water if it causes mucosal discomfort (SDCEP, 2016).
2.2.4. Dental Caries Risk:

The importance of preventing dental caries cannot be overemphasised. The need to maintain nutrition and body weight and difficulty with chewing often necessitates highly calorific and cariogenic food supplements (e.g. Fortisips by Nutricia). The following measures can be implemented to reduce the caries risk:

- The dental team should work with the dietitian team to keep the length of time these are used to a minimum, timing where possible limited to meal times and the mouth is rinsed after intake (Meurman and Gronroos, 2010).
- Sugar free medicines should be used wherever possible and discussed with the oncology team.
- Adults should use an alcohol-free fluoride mouth rinse at least once daily (0.05% NaF) at a different time from brushing. In addition, they should be prescribed 5,000ppm fluoride toothpaste for use twice daily and fluoride varnish (2.26% fluoride) should be applied twice a year (Public Health England, 2017).
- Children and young adults should have fluoride toothpaste, application of fluoride varnish and fissure sealants and fluoride mouthwashes appropriate to age (Public Health England, 2017) (SDCEP, 2016) (Kielbassa et al., 2006). In addition, 2800ppm fluoride toothpaste can be prescribed for use twice daily in those aged 10 years and above.
- Fluoride gel application in custom made trays for ten minutes daily has been recommended but compliance is poor (Thariat et al., 2012). This may be difficult for patients with trismus or after surgery and is not suitable for children.
- Further trials in this population are recommended before the widespread use of free calcium products (Tooth Mousse, GC) (Raphael and Blinkhorn, 2015).

2.2.5. Viral Infections:

Children and adults receiving bone marrow transplants often receive aciclovir as a prophylaxis if there is a high risk of viral infections. The facial and oral tissues may be sites of presentation of viral infections, such as those belonging to the herpes group. Anti-viral medication is usually prescribed by the oncology team (Ullmann et al., 2016) (Sanderr et al., 2015) (Glenny et al., 2010).

2.2.6. Fungal infections:

There is increased risk of oral fungal infection in patients receiving
chemotherapy and / or radiotherapy (Lalla et al., 2010). Antifungal medication should be used following detection of oral candida (Pappas et al., 2016) (Lalla et al., 2010). In some oncology centres, antifungal prophylaxis may be used routinely for children (Epstein et al., 1996).

Topical agents may be preferred to systemic agents due to lower risk of side effects (Bensadoun et al., 2011). However, there are inconsistent results of efficacy of topical agents and some oncology centres advise that systemic antifungal agents are preferable and each patient's risk should be identified before they are prescribed (Lalla et al., 2010).

The following are recommended in adults:

- Nystatin oral suspension 100,000 units per ml four times daily for at least 7 days and 48 hours after resolution (Pappas et al., 2016) (Lalla, et al., 2010) (BNF, 2017). Pastilles are difficult to dissolve in a dry mouth. Compliance may be poor due to unpleasant taste (SDCEP, 2016) (Lalla et al., 2010). Ideally sugar-free preparations should be used as nystatin to avoid an increased risk of dental caries.

- Miconazole oral gel 24mg/ml 10ml applied four times daily continued for 48 hours after resolution is an alternative (SDCEP, 2016) (Bensadoun et al., 2011).

- Systemic agents have more consistent efficacy and fluconazole is recommended for moderate or severe oropharyngeal candidiasis or unresponsive infection (Pappas et al., 2016). The regime is 50mg capsules or suspension daily for seven to fourteen days.

Miconazole and fluconazole are contraindicated in patients taking warfarin or statins (BNF, 2017).

For children appropriate recommended doses should be used as per the British National Formulary (BNF, 2017).

Denture hygiene is very important if there is fungal infection; dentures should be cleaned with a toothbrush / nailbrush and soaked in chlorhexidine mouthwash or dilute sodium hypochlorite. Miconazole oral gel should be applied to the fit surface prior to re-insertion, provided it is not contraindicated (SDCEP, 2016) (De Sanctis et al., 2016).

2.2.7. Mucositis:

The Oral Assessment Guide is the recommended tool to ensure the signs and symptoms of mucositis are observed and recorded (see Appendix 4 for a
modified version) (Eilers et al., 1988). It has been consistently judged to be user-friendly and appropriate for everyday clinical practice with adults and children, as well as a useful research tool (Gibson et al., 2010).

Several interventions for prevention and management of mucositis have been found to have some benefit but there is no consensus of best protocol. There is limited evidence for their efficacy in children. The strength of evidence is variable and may be specific to cancer type and treatment (Riley et al., 2015).

- The use of mucosal shields and intensity-modulated radiotherapy is to be encouraged since there is decreased severity of mucositis (Treister and Sonis, 2007).

- Intensive oral hygiene reduces mucositis (Treister and Sonis, 2007) (SIGN, 2006) (Stockman et al., 2006).

- Poorly fitting dentures or sharp teeth may exacerbate symptoms and should be corrected (Treister and Sonis, 2007).

- Difflam (benzydamine hydrochloride) 0.15% mouthwash reduces the frequency and severity of mucositis and is recommended. A regime of 15ml four to eight times daily starting before radiotherapy and continuing during and for two to three weeks afterwards is recommended (Nicolatou-Galitis et al., 2013).

- Chlorhexidine has not been shown effective and is not recommended for prevention or treatment of mucositis (Cardona et al., 2017) (McGuire et al., 2013).

- Oral cooling prior to chemotherapy is recommended where mucositis inducing chemotherapeutic agents are used (e.g. 5-FU) (Peterson et al., 2013).

- Patients receiving high dose chemotherapy or total body irradiation for stem cell transplantation are recommended intravenous keratinocyte growth factor-1 (palifermin) since there are promising effects on preventing mucositis. There is no benefit with palifermin taken as a mouthwash (Stockman et al., 2006) (Luccheses et al., 2016).

- There is insufficient evidence for intravenous amifostine for prevention of mucositis and this is not recommended (Nicolatou-Galitis et al., 2013).

- A number of topical agents have been used. There is insufficient evidence for use of topical application of antimicrobial pastes or lozenges, prostaglandins, corticosteroids, sucralate, allopurinol, acyclovir and these are not recommended (Stockman et al., 2006) (SIGN, 2006) (Saunders et al., 2013)

- Muso-adhesive oral rinses and gels have shown limited efficacy (Mugard,
Gelclair) (Allison et al., 2014) (Barber et al., 2007).

- Other palliative management recommended is 2% lidocaine mouthwash used prior to eating, fentanyl dermal patches, 2% morphine mouthrinse and systemic pain relief with morphine in severe cases (Treister and Sonis 2007) (Saunders et al., 2013).

- Low level laser therapy may be beneficial for prevention in patients having radiotherapy alone (Migliorati et al., 2013). It may also be of benefit in preventing oral mucositis in patients receiving hematopoietic stem cell transplantation conditioned with high-dose chemotherapy, with or without total body irradiation (Lalla et al., 2014).

- Zinc supplements taken orally may reduce mucositis in radiotherapy and chemotherapy (Yarom et al., 2013).

2.2.8. Xerostomia:

A recent systematic review and meta-analysis has been undertaken to estimate the effectiveness of available interventions for radiotherapy-induced xerostomia and hyposalivation. Results from the meta-analysis, which included six studies, suggest that both cevimeline and pilocarpine can reduce xerostomia symptoms and increase salivary flow compared to placebo, although some aspects of the relevant effect size, duration of the benefit, and clinical meaningfulness remain unclear. It concluded that randomised trials of available treatment modalities have produced unclear results and offer little reliable guidance for clinicians to inform evidence-based therapy.

In view of the above, the recommendations below are based on the current best available evidence:

**Flouride Supplementation:**

- Xerostomia increases the risk of dental caries. Flouride supplementation is recommended as outlined in section 2.2.4.

**Lubrication of the soft tissues:**

- Oral gel or lubricants (e.g. petroleum jelly based products (Vaseline) or emollients (Cetraben) are useful to coat and protect the lips and soft tissues.

**Reducing damage to the salivary glands:**

- Minimising the dose of radiotherapy to the parotid glands by IMRT is encouraged as has been shown to improve xerostomia-related quality of
life (Jensen et al., 2010) (Zhang et al., 2015) (Nutting et al., 2011).

- Amifostine given with radiotherapy has been shown to protect the salivary glands, with patients experiencing minor benefits, but there are significant side effects and it is not routinely recommended (Jensen et al., 2010) (Cancer Care Ontario, 2012).

**Salivary stimulation:**

- Pilocarpine is recommended after radiotherapy where some salivary function remains, provided there is no medical contraindication (Jensen et al., 2010). However, one review found that only half of patients respond (Davies and Shorthose, 2007). The dose is 5-10mg orally taken three times a day (SIGN, 2006). Side effects can be problematic so dose should be kept to a minimum. It may take more than two months to reach maximum effect (Nieuw et al., 2003). There is mixed evidence to recommend pilocarpine during radiotherapy, some studies have shown increase in unstimulated saliva flow up to 12 months afterwards (Jensen et al., 2010) (Yang et al., 2016).

- Stimulation by sugar free chewing gum may be recommended where there is some salivary function although there is a limited evidence base (Jensen et al., 2010) (Kaae et al., 2016). In addition, patients should be advised regarding the potential digestive side effects of xylitol, which include bloating, flatulence and diarrhoea.

- Acidic pastilles are to be use with caution as these may cause tooth erosion and sensitivity (e.g. Salivix (Provalia); SST (Medac)).

- There is low quality evidence that acupuncture results in a small increase in saliva. Acupuncture has minimal side effects and clinical trials are recommended (Jensen et al., 2010) (Furness et al., 2013).

**Saliva substitution:**

- For many patients, saliva replacement is the only option. Many use frequent sips of water (ideally non-carbonated and without acidic flavouring). Substitutes may improve patient’s perception of xerostomia.

- Saliva is difficult to replicate and there are several substitutes with little indication of which is most effective (Porter et al., 2010).

- It is important to avoid the use of acidic saliva replacements in dentate patients (e.g. Glandosane).

- Similarly, consideration should be given as to whether the substitutes contain fluoride.
- It is recommended patients sample alternative therapies to assess which suits them best. Gels may have longer duration of benefit. It is important to note that some products contain animal derived ingredients which need to be considered in the context of religion and also allergies / intolerances. If a preparation without fluoride is used, a fluoride mouthwash should also be used daily in dentate patients. The following are suggested:

- Saliva orthana (ASPharma) (contains porcine mucin; contains fluoride)
- Biotene Oral Balance Gel (GSK) (new formulation not acidic; contains milk, egg white)
- BioXtra Gel (Molar) (Shahdad et al., 2005) (contains milk, egg white; contains fluoride)

2.2.9. Dentures / Obturators:

If dentures are left out during the period of mucositis they should be cleaned and kept moist. If candidal infection has been diagnosed this should be treated.

Obturators should not be discontinued. If painful a clinical examination and adjustment is indicated.

2.2.10. Foam swabs / Oral Cleanser / Gauze:

Foam swabs are not as effective as a toothbrush but there may be times, for example post-surgery or in advanced disease, when either foam swabs or gauze are necessary (Addems et al., 1992). Oral cleanser sticks (e.g. MC3), may also be used. Use soaked in chlorhexidine three to four times daily. Care should be taken with oral care if patients are at risk of aspirating following surgery / radiotherapy. Patients should be sitting up and minimal amount of fluid used and aspiration should be available. Nursing staff should be trained in oral care and family and carers may be involved. Normal toothbrushing should be resumed as soon as possible.

2.2.11 Dietary Advice:

Avoidance of certain food, drinks and mouthwashes can help to prevent discomfort.

The following should be avoided:

- Hard food, spicy food, strongly flavoured toothpaste: these traumatise the tissues
- Alcohol (especially spirits), tobacco: these exacerbate xerostomia
- Fizzy drinks, acidic fruit and fruit drinks: these contribute to tooth surface loss and sensitivity, especially in the dry mouth where there is reduced saliva buffering.

2.2.12 Dental Treatment:

Dental treatment should be avoided during the period of cancer therapy because the mouth may be very sore and there is risk of systemic infection during the period of mucositis. If the patient is having chemotherapy the suppressive effect on the bone marrow may cause low platelets, low white cells and anaemia. Therefore, special care needs to be taken and timing of interventive dental treatment should be agreed with the haematologists or the oncology team. Pulp treatment of primary teeth is contra-indicated in immunocompromised patients (Rodd et al., 2006). Extractions are always contraindicated after radiotherapy to the head and neck area, careful patient pre-treatment assessment and planning should avoid the need.

2.2.13. Obturators:

Maxillary / mid face defects can be rehabilitated using surgery and / or obturated using a prosthesis. Developments in surgical techniques have resulted in wider use of microvascular free tissue transfer to provide vascularised hard and soft tissue for reconstruction, commonly at the time of tumour resection. However, as an alternative to surgical reconstruction, defects can be obturated using a removable prosthesis. This may be more relevant for patients with increased surgical morbidity or risk, but other factors require to be assessed.
2.3. FOLLOWING CANCER THERAPY

2.3.1. Monitoring:

- All oncology patients should be monitored for local recurrence, metastatic lesions in the head and neck region (daSilva et al., 2012), and a second malignant lesion (Morton et al., 2014).

- Furthermore, susceptibility to dental disease can be lifelong following cancer therapy (Hong et al., 2018) (Hong et al., 2010) (Jensen et al., 2010).

- It is the dental team’s responsibility to ensure patients fully understand the long-term dental adverse effects that can follow treatment for malignant disease and emphasise good oral care and prevention (Gupta et al., 2015).

- Individualised oral health prevention and monitoring programme should be established for each patient reflecting the treatment they have received, their particular needs and risk factors and the presence of active dental disease (Public Health England, 2017).

- Regular oral healthcare monitoring should be undertaken by a designated member of dental staff in close liaison with the dental hygienist/therapist. The recall interval is based on the patient’s risk assessment but is likely to be no less frequent than three monthly, at least in the first instance (NICE, 2004).

- Good communication between the oncology team, the patient, and all members of the dental team is essential (Tremblay et al., 2016).

2.3.2. Dental Caries Risk:

The risk of dental caries following cancer therapy will depend on the type of treatment the patient has received (Hong et al., 2018) (Hong et al., 2010). The following factors increase the risk of dental caries:

- Salivary hypofunction caused by damage to the salivary glands during radiotherapy, leading to xerostomia and a more cariogenic oral microflora (Gawade et al., 2015).

- Patients choosing cariogenic foods and drinks due to altered taste (Bressan et al., 2016), mucositis (Riley et al., 2015), and difficulties with mastication and swallowing (Cousins et al., 2013).

- The prescription of a cariogenic diet and nutritional supplements by dieticians because of weight loss, malnutrition and difficulties with eating (Talwar et al., 2016).

- Poor oral hygiene due to difficulties with toothbrushing/interdental aids as a result of limited oral opening (Gebre-Medhin et al., 2016) (Macfarlane et al.,...
2012), or reduced motivation secondary to psychosocial distress (Dunne et al., 2017).

- The presence of enamel defects and dental hypoplasia secondary to radiotherapy and chemotherapy in childhood (Gawade et al., 2015).

2.3.3. Gingival and Periodontal Risk:

- Bone marrow transplant patients on ciclosporin may need more frequent hygienist support to help maintain health in the presence of gingival hyperplasia (Aimetti et al., 2008).

- Oral hygiene instructions, supra- and subgingival scaling, polishing, and gingival curettage should be carried out in the first instance with this having been found to reduce the need for gingivectomy (Kantarci et al., 1999).

- Patients who have received radiation therapy to the head and neck region are at increased risk of progressive, uncontrolled periodontal tissue breakdown and/or ORN (Epstein and Stevenson-Moore, 2001).

- This is likely due to reduced repair capacity of the periodontium following direct irradiation with progressive widening of the periodontal ligament, destruction of the lamina dura and progressive loss of attachment having been reported (Epstein and Stevenson-Moore, 2001).

- Furthermore, the risk of periodontal infection is increased because of radiation-induced hyposalivation, the concomitant increased plaque accumulation, and the shift in oral microflora.

- There do not, however, appear to be any significant long-term changes to periodontal pathogens following head/neck radiation therapy (where treatment of the periodontium had included irrigation with chlorhexidine) (Al-Nawas and Grötz, 2006).

- Poor oral health status post-radiotherapy has been found to increase the risk of ORN (Katsura et al., 2008). As such any evidence of periodontal disease should be treated rigorously but nonetheless causing minimal damage to the adjacent structures; trauma to the soft tissues can also predispose to ORN (Kielbassa et al., 2006).

2.3.4. Preventive advice and fluoride supplementation:

- Dietary analysis and advice should be undertaken at frequent intervals with an emphasis on reducing the amount and frequency of sugars and acids in the diet and encouraging a healthy balanced diet (Public Health England, 2017). The patient’s diet is likely to change during the post-treatment period as their health improves, and ongoing advice and support for behaviour
change is required (Public Health England, 2017).

- Close liaison with the dietician is needed throughout the post-treatment period (Talwar et al., 2016). It is important to balance the need for good nutrition and weight gain against the risk of developing dental caries.

- Plaque and gingival scores, such as the Basic Periodontal Examination (BPE), should be regularly monitored by the dental hygienist/therapist looking after the patient. Oral hygiene advice should be individualised and tailored to the specific needs of the patient (Public Health England, 2017).

- The role of fluoride in the continuing prevention of dental caries is essential to the maintenance of oral health. Teeth should be brushed twice daily with a fluoridated toothpaste. Strong evidence shows that toothpastes containing higher concentrations of fluoride are more effective at controlling caries. It is clear that low fluoride toothpastes (those containing less than 1,000ppmF-) are ineffective at controlling caries. The following fluoride content of toothpaste is recommended for patients giving concern to the dentist (e.g. those with active caries, dry mouth and other predisposing factors which may be linked to cancer therapy) (Public Health England, 2017)
  - Children 0-10 years old: 1350-1500ppm
  - Children aged 10-16 years old: 2800ppm
  - Adolescents / adults aged 16 years old and over: 2800ppm - 5000ppm

- The professional application of fluoride varnish (2.26% NaF) has a caries inhibitory effect (Marinho et al., 2013). Applications should be twice yearly or more frequently (Public Health England, 2017).

- A daily fluoride mouthwash can be advised to increase the amount of available fluoride (Marinho et al., 2016). This is only recommended for children aged eight years and over and adults (Public Health England, 2017).

- There is insufficient evidence in children / adolescents without xerostomia to recommend the use of casein phosphopeptide-amorphous calcium phosphate (CPP-ACP) products such as Tooth Mousse® over fluoride products in the prevention and treatment of early carious lesions (Raphael and Blinkhorn, 2015). However, in patients with Head and Neck cancer who have xerostomia due to radiotherapy, there is depletion of calcium and phosphate in the saliva and hence these products may be of benefit, particularly as they are available in sweet flavours which may be better tolerated.

- There is also insufficient evidence to support the use of chlorhexidine
2.3.5. Xerostomia:

Salivary stimulants and saliva replacement products are outlined in section 2.2.8 explanatory notes

2.3.6. Smoking cessation:

Smoking cessation support should be ongoing and patients should be encouraged to reduce alcohol consumption (Hashibe et al., 2009). Support to stop the use of smokeless tobacco and betel quid should also continue (Gupta and Johnson, 2014).

2.3.7. Abnormal blood counts

Patients on maintenance chemotherapy / a history of low blood profiles due to haemato-oncology disease, should have a full blood count performed within the 24-48 hours period prior to any proposed dental treatment that might result in bleeding/bacteraemia. The results of such blood tests should be discussed with the patient's medical team and appropriate precautions taken.

2.3.8 Herpes labialis

Herpes labialis can be a chronic problem. Topical aciclovir (5% cream applied five times daily for five to ten days, starting at first sign of attack) is effective (Arduino and Porter, 2006) (BNF, 2017).

2.3.9 Limited mouth opening:

- Despite better focused radiation dose and improved screening, progressive jaw stiffness and limitation of opening remains a common complication (Gebre-Medhin et al., 2016). Reduction of mouth opening due to tumour recurrence should be excluded.

- In the event of limitation, physical therapy modalities e.g. passive and active stretching exercises, and the use of devices for stretching the muscles of mastication e.g. Therabite jaw motion rehabilitation system, Dynasplint Trismus System, and stacked tongue depressors, are the mainstay of treatment (Rapidis, et al., 2015).

- Evidence is conflicting, with one recent systematic review finding that no stretching technique was superior to others regarding either prevention or treatment of trismus (Kamstra et al., 2013) and another suggesting that the use of a jaw-mobilising device yielded better results than no exercise in
patients with radiotherapy-induced trismus (Scherpenhuizen et al., 2015).

- Starting therapy early and compliance with exercises were important factors in the success of treatment (Kamstra et al., 2013).
- Other therapy modalities include drug therapy such as pentoxifylline to improve microcirculation and tissue oxygenation, although the evidence for this intervention is very weak (Chua et al., 2001).
- Botulinum toxin injection can be used to reduce pain associated with trismus, although it does not improve mobility (Hartl et al., 2008).
- Coronoidectomy can be considered to increase the range of motion (Bhrany et al., 2007). Increasing levels of trismus should be investigated for potential local recurrence (Rapidis et al., 2015).

### 2.3.10 Growth and Development:

- In children, general growth and development including facial growth and dental development should be closely monitored (SIGN, 2013).
- Survivors of childhood cancer who received radiotherapy, chemotherapy and total body irradiation with high-dose chemotherapy prior to stem cell transplant are all at an increased risk of dental developmental abnormalities including agenesis, microdontia, hypoplasia, root stunting and enamel defects, in addition to xerostomia (Pedersen et al., 2012) (Cubukcu et al., 2012) (Verterbacka et al., 2012) (Hsieh et al., 2011).

- The risk of dental abnormalities increases by younger age at treatment, higher doses of radiation and/or chemotherapeutic agents, and combined treatment (Gawade et al., 2015).
- This has implications in future dental care for the restorative specialist.

### 2.3.11 Orthodontics:

- The decision to embark upon orthodontic treatment must to be taken carefully, and discussed with the patient’s medical team in advance.
- Overall health, susceptibility to dental caries and response to oral health prevention regimes should be assessed (Wishney, 2017).
- Consideration must be given to the forces to be used and length of time that the patient will be in active orthodontic treatment. This is due to possible damage/effects that may have occurred previously to the roots of the teeth (Gawade et al., 2015). When roots have either been damaged or not developed properly, orthodontic work can have detrimental effects on the root structure so the advantages and disadvantages of such treatment must be
explained carefully to the patient.

- The effects of antiresorptive agents should be considered carefully if orthodontic extractions are anticipated. The risk of medication-related osteonecrosis following dental extraction in patients who have received antiresorptive agents for cancer treatment is approximately 1% (range 0.2%-6.7%) (Dodson, 2015).

- Oral bisphosphonates have been shown to inhibit orthodontic tooth movement, prolong treatment time, and increase the odds of poor space closure and poor root parallelism in a small retrospective cohort study (Lotwala et al., 2012).

- There are currently no human studies examining the effects of intravenous bisphosphonates on orthodontic tooth movement. However the general consensus is to avoid orthodontic treatment when IV bisphosphonates are being administered and for a period after cessation.

2.3.12 Restorations:

- Where appropriate, a restorative material with fluoride release may be used.

- Of note, conventional glass ionomer restorations have been found to perform more poorly than resin modified glass ionomer, composite resin, and amalgam restorations in patients who have been treated with radiotherapy (Hong et al., 2018).

- In those patients who have xerostomia related to radiation therapy, cervical caries is problematic and particularly so in those patients who fail to comply with preventive measures. Conservative restorative management of cavitated lesions is to be recommended in the first instance. Full / partial coverage crowns should be provided only when the patient can demonstrate good oral hygiene; caries can quickly progress around the margins of full / partial coverage crowns with the potential for eventual ‘carious amputation’ of the crown. Should a full coverage restoration be warranted, the margins should be subgingival (Chung and Sung, 2006).

- Routine restorative treatment must be delayed until the patient is in remission, when a careful study of the medical history should be made.

- Some children may have developed other medical complications as the result of cancer treatment (e.g. cardiomyopathy) with possible implications for their dental management.

2.3.13 Dental extractions:

- Where possible, extraction of teeth from irradiated sites should be avoided due to the risk of ORN (see section 2.3.17).
Cancer patients who have received a bisphosphonate or other anti-resorptive drug therapy are also at increased risk of medication related osteonecrosis of the jaw (MRONJ) and dental extractions avoided (Ruggiero et al., 2006) (see section 2.3.18).

There is currently no effective treatment for ONJ and MRONJ and they can adversely affect the quality of life for patients.

A systematic review has estimated the total incidence of ORN after tooth extraction in irradiated patients to be 7% (Nabil and Samman, 2011). When extractions were performed in conjunction with prophylactic HBOT, the incidence was 4% while extraction in conjunction with antibiotics gave an incidence of 6%.

However, there is no clear evidence that HBOT reduces the chance of ORN following tooth extraction in an irradiated field. Its use may be considered in the context of clinical trials (NICE-NG36 2016).

Although there is no conclusive evidence regarding pre-extraction antibiotic prophylaxis to prevent ORN, the general consensus would recommend antibiotic prophylaxis and continued antibiotics until completion of healing. Co-amoxiclav / amoxicillin (metronidazole in those allergic to penicillins) are generally the drugs of choice (Koga et al., 2008) (Ruggiero et al., 2006). Discussion with the oncology team is essential.

Some studies recommend the use of alcohol free 0.2% chlorhexidine gluconate mouthwash prior to extractions and the use of low-adrenaline/adrenaline free local anaesthesia may also reduce the risk of ORN. (Koga et al., 2008). The evidence regarding this approach is not clear.

Any extractions completed should be performed with minimal trauma and, where possible, soft tissue primary closure obtained (Nabil and Samman, 2011).

Patients are at particular risk of ORN when:

- The total radiation dose exceeded 60Gy (Nabil and Samman, 2011) (Clayman, 1997).
- The dose fraction was large with a high number of fractions.
- There is local trauma as the result of a tooth extraction (especially mandibular extractions), uncontrolled periodontal disease or an ill-fitting prosthesis.
- The person is immunodeficient.
- The person is malnourished.

Where there is a high risk of ORN and where it is clinically feasible, serious consideration to root canal therapy and restoration/crown amputation should be made (Kielbassa et al., 2006) (Chung and Sung, 2006) (Ruggiero et al., 2006).
The risk of medication-related osteonecrosis (MRONJ) in patients who have received bisphosphonates and/or antiresorptive agents for cancer treatment should also be considered when dental extractions are being discussed (see section 2.3.18). Where possible, dental extractions should be avoided and, as in the case for risk of ORN, teeth stabilised with root canal treatment (SDCEP, 2017).

2.3.14 Dentures:

- Dentures should be avoided wherever possible. Appliances will contribute to plaque retention and oral disease, particularly when there is xerostomia.
- When dentures are essential to ensure good function following cancer treatment, their construction will aid the ability to chew solid food and, by extrapolation, promote social adaptation and weight gain.
- Removable prosthetic appliances should be removed and left out of the mouth overnight and subjected to a cleansing regimen involving careful brushing with household washing up liquid and warm water to remove all visible debris and immersion in a sodium hypochlorite if they have no metal parts (Milton’s) solution (1% sodium hypochlorite in a 1:80 dilution). Chlorhexidine mouthwash can also be used.
- For those edentulous patients who have xerostomia, a suitable oral lubricant/artificial saliva solution or gel can be applied to the fit surface of their prosthesis prior to reinsertion; this may help to ameliorate xerostomia.
- Artificial salivas with an acidic base (e.g. Glandosane) should be avoided in dentate patients (Holliday et al., 2015).
- Artificial saliva reservoirs, incorporated into complete or partial prostheses, have been shown to relieve xerostomia symptoms temporarily (Mendoza and Tomlinson, 2003).
- In the event of oral candidal infection, antifungals should be prescribed for at least two consecutive weeks:
  - Miconazole varnish or gel applied to fit denture surface. This should be avoided if the patient is taking warfarin; the anticoagulant effect is enhanced by miconazole.
  - Nystatin powder- 500,000-1000000 units per application of Viscogel can be incorporated into a denture soft lining material. The nystatin powder is added when the powder and liquid of the liner are mixed. The fungicidal activity of such modified lining materials reduces with time and as such requires to be changed on a regular basis e.g. between seven and fourteen days (Falah-Tafti et al., 2010) (Geerts et al., 2008).
  - Tea tree oil (M. Alternifolia) mixed with the Coe Comfort tissue conditioner has an anti-fungal effect and could be used as an alternative therapy for denture stomatitis which is resistant to traditional therapies (Catalán et al., 2008).
  - Microwave disinfection of maxillary complete dentures has also been found to be effective (Neppelenbroek et al., 2008).
  - Miconazole / Fluconazole may be required for resistant infections but are
contraindicated for patients on warfarin (BNF, 2017).

- Appliance wear should be discontinued if the mouth becomes painful and advice must be sought from the supervising consultant. Trauma from dentures has been implicated in an increased risk of MRONJ. Modification or replacement of dentures may be required to alleviate symptoms.

2.3.15 Dental Implants:

- Osseointegrated implants may facilitate effective oral rehabilitation following cancer treatment (including radiotherapy). They can be used to support fixed or removable prostheses.

- The provision of implants should take into consideration the patient’s prognosis, published national guidelines on their use, and where relevant evidence regarding their use in head and neck oncology patients (Alani et al., 2012) (Barber et al., 2011).

Careful planning and appropriate patient selection are essential prior to any such intervention (RD-UK, 2016).

- Where full planning can be undertaken pre-operatively, placement of implants at the time of tumour resection may be beneficial for suitable patients where continuity of the mandible is either preserved or reconstructed, or for patients requiring significant maxillary defects to be obturated by way of a prosthesis.

- Where segmental resection with reconstruction of the mandible is undertaken, implant survival and usefulness may be improved by delayed placement after suitable prosthodontic planning.

- Where post-operative radiotherapy is part of the initial plan, primary implant placement may be preferred, although it may reduce time and opportunity for the planning of ideal implant location (Javed et al., 2010).

- For most patients, placement of osseointegrated implants will be a consideration in response to ongoing problems with oral function after cancer treatment. Management at this time allows a full detailed assessment of the patient’s prognosis, risk factors (smoking, alcohol, oral hygiene, radiotherapy fields and their impact) as well as consideration of other factors including residual anatomy, reconstructive tissue grafts (both bone and soft tissues), metal reconstruction frameworks, and overall oral function, including tongue mobility, mouth opening and swallowing function and airway protection. The use of computerised planning and surgical stents is advocated for optimal outcomes.

- While implants may be placed in irradiated bone, careful case assessment is necessary. Failure rates are higher than in non-irradiated bone and higher in the maxilla than in the mandible (Barber et al., 2011).
- Osteoradionecrosis is an acknowledged risk of implant placement in irradiated tissues.
- Failure is less likely with a radiation dose lower than 45Gy.
- It has been suggested that a delay of one to two years after irradiation for implant placement and a further 6 months delay for abutment connection reduces risk but further review of this is necessary (Dholam and Gurav, 2012).
- There may be an increased risk of implant failure in free flap bone that has been irradiated (Barrowman et al., 2011).
- There is no good quality evidence for the use of hyperbaric oxygen for patients who require implant placement in irradiated bone (Esposito et al., 2008).
- While zygomatic implants may be used to retain obturators as an alternative to free flaps, the efficacy of zygomatic implants in aiding maxillary obturation is not clear (Schmidt et al., 2004).
- Implant-supported prostheses and complex conventional prostheses require long-term review by the restorative dentistry consultant.
- The placement of implants in patients who are being treated with intravenous high potency bisphosphonates for cancer, is not recommended due to the higher risk of MRONJ (SDCEP, 2017).

2.3.16. Obturators:

- Obturators should be reviewed regularly. They may require frequent attention with adjustment or remake.
- Obturators should not be left out at night for the six months following treatment and may be worn at night for longer dependent on patient comfort and function, e.g. breathing, and with the approval of and regular review by the treating restorative dentistry consultant.
- Where longer-term appliance wear is continued, prosthesis hygiene must be emphasised with patients and a daily period of cleansing of the prosthesis as above is mandatory.
- Maxillary / mid face defects can be rehabilitated using surgery and / or obturated using a prosthesis. Developments in surgical techniques have resulted in wider use of microvascular free tissue transfer to provide vascularised hard and soft tissue for reconstruction, commonly at the time of tumour resection. However, as an alternative to surgical reconstruction, defects can be obturated using a removable prosthesis. This may be more relevant for patients with increased surgical morbidity or risk, but other factors require to be assessed.
- The level of evidence available to support surgical reconstruction using free
flaps versus prosthetic obturation of maxillary and mid-face defects remains low.

- Maxillectomy is sufficiently uncommon that patient numbers for analysis remain low. While larger defects are increasingly surgically reconstructed this has an impact on both the feasibility of as well as an opportunity to assess the effectiveness of prosthetic obturation / reconstruction (Rogers et al., 2003) (Moreno et al., 2010)

- Other factors such as any surgical flap which has been used, the final dimensions and morphology of the defect and adjunctive (chemo) radiotherapy all affect success, as does the initial dental health status of the patient and previous prosthetic experience.

- The most significant predictor of obturator function is the size of the defect. Statistically better obturator function is associated with defects where resection of the soft palate is one third or less and resection of the hard palate is one quarter or less (Rogers et al., 2003) (Kornblith et al., 1996).

- Statistically significant higher obturator speech scores are achieved as the resection volume of soft palate decreases (Kornblith et al., 1996). However, whether obturation or free flap reconstruction of maxillary and mid-face defects provides better oral rehabilitation remains controversial.

- While patients may prefer to have a reconstruction, which brings a sense of more permanent replacement of the lost tissues rather than a defect that is always evident on removal of the obturator, the nature of the reconstruction may make prosthetic rehabilitation more problematic in the longer term.

2.3.17. Osteoradionecrosis:

- Osteoradionecrosis (ORN) of the jaws is one of the most severe and debilitating complications following radiation therapy for head and neck cancer patients in the proven absence of tumour, and may be a major complicating factor following surgery or trauma to a previously irradiated maxilla or more commonly mandible. Radiation-induced fibrosis, and reduction of fibroblastic activity in the irradiated area, produces atrophic tissue with damage to micro-vessels, resulting in vascular insufficiency which rather than infection contributes to bone death (Costa et al., 2016) (Nadella et al., 2015) (McLeod et al., 2010) (Lyons and Ghazali, 2008).

- Risk factors include the total radiation dose, modality of treatment, fraction size and dose rate, oral hygiene, timing of tooth extractions or other invasive procedures the continued use of tobacco and alcohol may further increase the incidence of ORN (Wang et al., 2017) (Maesschalck et al., 2016).

- This condition is characterised by deep-seated bone pain often with a purulent discharge that may include sequestrated bone and may result in significant
bone loss. If treated inadequately or left untreated it can be majorly debilitating and significantly impair quality of life (Rice et al., 2015) (Silvestre-Rangil and Silvestre, 2011).

- Basic criteria for staging of ORN:
  - **Stage 0**: mucosal defects only; bone exposed
  - **Stage I**: radiological evidence of necrotic bone, dento-alveolar only
  - **Stage II**: positive radiographic findings above ID canal with denuded bone intraorally
  - **Stage III**: clinically exposed radionecrotic bone, verified by imaging techniques, along with skin fistulas and infection with addition of potential or actual pathological fracture. Radiological evidence of bone necrosis within the radiation field, where tumour recurrence has been excluded (Dhanda et al., 2016) (Deshpande et al., 2015) (Karagozoglu, et al.. 2014) (Shaw and Dhanda, 2011) (Notani, et al.. 2003) (Støre and Boysen, 2000).

- Strenuous efforts should be made to avoid ORN by careful oral health monitoring and ensuring prevention compliance, timely dental treatment and dealing promptly with oral trauma (Raguse et al., 2016) (Butterworth et al., 2016) (Chronopoulos et al., 2015) (Kanatas et al., 2002).

- Oral trauma can be reduced by implementation of a soft diet and adjustment or removal of any denture that could be contributing to trauma. Extractions are to be avoided where possible, particularly in the mandible (Wang et al., 2017) (Beech et al., 2017).

- The Antioxidant agent, pentoxifylline (PTX), facilitates microcirculation, and inhibits the inflammatory mechanisms, promotes fibroblast proliferation and the formation of extracellular matrix. Tocopherol (vitamin E) protects the cell membrane against peroxidation. A synergic effect has been observed between PTX and tocopherol in the treatment of ORN. These are accessible, well-tolerated and safe drugs at a suggested daily dosage of: PTX dose of 800mg/day and vitamin E 1000 IU/day. The evidence base for using these drugs is developing, and there is a lack of randomised controlled clinical trials supporting the use of these drugs. Any units using these drugs for the management or prevention of ORN should regularly audit their patient outcomes. (Patel et al., 2017) (NICE-NG36, 2016) (Patel et al. 2016) (Rice et al., 2015) (Robard et al., 2014) (McLeod et al., 2012) (Delanian et al., 2011) (Kahenasa et al., 2012).

- High dose antibiotic regimes should be instigated when symptomatic ORN is diagnosed and continued until a definitive treatment outcome or symptom relief is achieved. In more chronic cases the presence of Actinomycoses must be
considered as this will alter the dynamics of treatment protocols (Hall, 2008).

- The antibiotic of choice should be broad spectrum with a wide field of action such as amoxicillin with clavulanic acid; antibiotic prophylaxis prior to extraction or sequestrectomy should be given and continued until mucosal integrity has occurred (Hall, 2008). It is recommended that antibiotic treatment is initiated prior to surgery and continued through the surgical phase of ORN management, and post-surgery (Kanata et al., 2002).

- Localised disease control to remove sequestra and other debris from intra-oral defects in combination with adjunctive antibiotics is completed to gain pain relief. This treatment also facilitates sampling of material for culture and histopathology to establish both the non-malignant potential of diseased tissue and specificity and the sensitivity of microbial population to antimicrobial therapy (Shaw and Butterworth, 2011).

- There is a risk of serious complications developing after radiation cancer treatment due to late radiation tissue injury (LRTI).

- HBOT involves breathing oxygen under increased atmospheric pressure in a specially designed chamber. It is used as a treatment to improve oxygen supply to damaged tissue and stimulates healing. For patients with LRTI affecting tissues of the head, & neck, HBOT can be associated with improved outcome (Dieleman et al., 2017).

- However, there is no clear evidence that HBOT reduces the chance of ORN following tooth extraction in an irradiated field (only consider its use when involved with clinical trials (NICE-NG36, 2016).

- Indeed, there is an increased risk of tumour recurrence in patients who receive HBOT (Dieleman et al., 2017) (Shaw and Dhanda, 2011).

- In advanced chronic cases, the extent of involvement of bone necrosis must be established. This can be via imaging cone bean CT r chemical markers, such as tetracycline to establish the healthy vital bone margins at surgery (Paulkte et al., 2010). This is then followed by radical ablative surgery to remove all the necrotic bone and soft tissue, including hemi-mandibulectomy and reconstruction with either a pedical or microvascular free flap. These procedures aim to achieve closure of orocutaneous fistulae and restore function and aesthetics (NICE-NG36, 2016) (Rice et al., 2015) (Zaghi and Hendizadeh, 2014) (Gevorgyan et al., 2013) (Baumann et al., 2011).

2.3.18 Medication related osteonecrosis of jaw (MRONJ):

- MRONJ is an area of exposed bone in the jaw persisting for more than 8 weeks with no history of radiation therapy while having undergone a bisphosphonate or other anti-resorptive drug therapy. These medications are used in the management of some cancers, such as bone cancers,
myeloma and metastases (Ruggiero et al., 2014).

- The incidence of MRONJ in adults when these medications are given in cancer patients has been reported as between 0.8% - 12%, including spontaneous cases and those following invasive dental procedures. The risk of MRONJ following dental extraction in patients who have received antiresorptive agents for cancer treatment is approximately 1% (range 0.2%-6.7%) (Dodson, 2015).

- There is very little evidence on MRONJ in children following bisphosphonates, denosumab, or bevacizumab therapy (SDCEP, 2017) (Hernandez et al., 2017) (Ngan et al., 2013). Although no cases reports of MRONJ in children have been published to date, there is little knowledge on long-term effects.

- A staging system should be used to classify the extent of existing MRONJ. The most commonly used system has been described by the American association of Oral and Maxillofacial surgery (Ruggiero et al., 2014):

  - **At Risk:** No apparent necrotic bone in patients who have been treated with oral or intravenous bisphosphonates
  - **Stage 0:** No clinical evidence of necrotic bone but nonspecific clinical findings, radiographic changes, and symptoms
  - **Stage 1:** Exposed and necrotic bone or fistulas that probes to bone in patients who are asymptomatic and have no evidence of infection
  - **Stage 2:** Exposed and necrotic bone or fistulas that probes to bone associated with infection as evidenced by pain and erythema in the region of exposed bone with or without purulent drainage
  - **Stage 3:** Exposed and necrotic bone or a fistula that probes to bone in patients with pain, infection, and ≥ 1 of the following: exposed and necrotic bone extending beyond the region of alveolar bone (i.e. inferior border and ramus in mandible, maxillary sinus, and zygoma in maxilla) resulting in pathologic fracture, extraoral fistula, oral antral, or oral nasal communication, or osteolysis extending to inferior border of the mandible or sinus floor

- Suggested interventions for preventing MRONJ include antibiotics and / or antibacterial mouthwashes administered before and after dental extractions, insertion of plasma rich in growth factor (PRGF) into the dental socket post extraction and wound closure by primary or secondary intention. More frequent dental examinations, namely three monthly, have also been proposed (Beth-Tasdogan et al., 2016).

- Suggested management for the treatment of MRONJ is stage specific and can be classified into non-surgical and surgical treatment.

- Non-surgical treatment options include: antiseptic treatment (chlorhexidine
mouthwash), antibiotics, drug treatment with teriparatide, pentoxifylline and α-tocopherol in combination with anti-microbial therapy, ozone therapy, hyperbaric oxygen, and low level laser therapy, platelet rich plasma have all been described.

- Surgical treatment options include: sequestrectomy, debridement, resection, immediate reconstruction and extraction of teeth within exposed necrotic bone. Autofluorescence-guided versus tetracycline fluorescence-guided bone surgery has also been described.

- The quality of evidence to support any of these approaches is currently is low or very low.

2.3.20 Discharge:

- For the majority of patients with radiation-induced side effects, discharge to the care of a primary care practitioner should be possible when the immediate post-treatment side effects have settled, diet modification has been addressed to reduce frequent intake of cariogenic food and drinks, consistently good oral hygiene is re-established and the use of topical fluoride products is comfortably tolerated. Where this is difficult to achieve, longer-term specialist support is advocated to minimise problems.

- However, even for patients discharged to primary care with good compliance and low initial evidence of pathology, the higher risk of caries and periodontal disease development and ORN will mean that they should have more frequent follow up than other patients in the primary care setting.

- Recall interval should be determined on an individual basis dependent on risk factors and the presence of active dental disease. Patients who persist with long-term energy-dense diets high in refined sugars and dietary supplements must be monitored closely for caries development (Public Health England, 2017)

- Life-long follow up for children is advised due to the late effects of cancer therapy.
REFERENCES


TABLE 1: GENERAL NURSING ORAL CARE GUIDELINES

1. PRIOR TO CANCER THERAPY

<table>
<thead>
<tr>
<th>Objective</th>
<th>Nursing Action</th>
</tr>
</thead>
</table>
| 1. Ensure all patients have been seen for a comprehensive assessment by a Dental Surgeon prior to cancer therapy | • For patients with head and neck cancer, patients should be identified for dental assessment at the multidisciplinary meeting and an assessment arranged  
• For all other patients, complete the Oral Health Screening Chart and Referral (Appendix 2 and 4) and forward to dental team  
• Liaise with the dental team to develop and implement an individual care plan |
| 2. Advice on the oral side effects of treatment                           | • Provide written information on side effects of treatment (Appendix 5)  
• Give support and encouragement                                           |
| 3. Preventive advice                                                      | • Dietary advice in liaison with the Dietitian  
• Provide written information (Appendix 5)                                  |

* Advise About Support Groups: Cancer BACUP: Changing Faces: Let’s Face It; Macmillan Cancer Support
### 2. DURING CANCER THERAPY

<table>
<thead>
<tr>
<th>Objective</th>
<th>Nursing Action</th>
</tr>
</thead>
</table>
| **1. Maintenance of oral hygiene** | • Provide advice and assistance where appropriate  
• Follow Practical Oral Care *(Appendix 3)* |
| **2. Inspection of the oral cavity should be carried out daily** | • The Oral Assessment Guide *(Appendix 4)* should be completed daily and placed in the patient’s individual care plan; contact the dental team for guidance prior to completion if required  
• Document findings in the patient’s individual care plan to monitor any changes  
• Refer to the dental team when indicated |
| **3. Monitor compliance in performing oral care** | • Supervise and provide assistance; give instructions to carers where appropriate  
• Give support and encouragement |
| **4. Pain control** | • Give topical / systemic analgesia, as directed |
| **5. Oral candidal infections (Thrush)** | • Give topical / systemic antifungal agents, as prescribed  
• If chlorhexidine gluconate mouthwash and nystatin suspension are prescribed, stagger their use by one hour |
| **6. Manage xerostomia** | • Give advice to help with a dry mouth  
• Ensure recommended saliva substitute is prescribed and used when appropriate |
### 3. AFTER CANCER THERAPY

<table>
<thead>
<tr>
<th>Objective</th>
<th>Nursing Action</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Arrange follow-up visit to the dental team</td>
<td>• Provide the patient or carer with a contact telephone number&lt;br&gt;• Arrange an appointment&lt;br&gt;• To ensure follow up occurs when the patient is discharged, an oral care entry should be made in the summary notes / discharge letter</td>
</tr>
<tr>
<td>2. Reinforce preventive messages</td>
<td>• Provide equipment for home care where appropriate&lt;br&gt;• Ensure patient information leaflet has been provided to support the advice given</td>
</tr>
<tr>
<td>Acute Change</td>
<td>Explanatory Notes</td>
</tr>
<tr>
<td>--------------------</td>
<td>------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td><strong>1. Mucositis</strong></td>
<td>• Acute inflammation of the mucosa</td>
</tr>
<tr>
<td></td>
<td>• White/yellow fibrinous slough, often with ulceration</td>
</tr>
<tr>
<td></td>
<td>• Painful to speak/eat/swallow</td>
</tr>
<tr>
<td></td>
<td>• Portal for microbial entry</td>
</tr>
<tr>
<td></td>
<td>• Healing complete 2-3 weeks post-completion cancer therapy</td>
</tr>
<tr>
<td><strong>2. Blood Changes</strong></td>
<td>• Anaemia</td>
</tr>
<tr>
<td></td>
<td>• Neutropenia</td>
</tr>
<tr>
<td></td>
<td>• Thrombocytopenia</td>
</tr>
<tr>
<td></td>
<td>• Present from commencement of cancer therapy until up to 4 weeks post therapy</td>
</tr>
<tr>
<td><strong>3. Immuno-suppression</strong></td>
<td>• Increases susceptibility to bacterial/candidal/viral disease</td>
</tr>
<tr>
<td></td>
<td>• Exacerbates pre-existing periodontal disease</td>
</tr>
<tr>
<td><strong>4. Changes in Salivary Flow/Composition</strong></td>
<td>• Saliva becomes thick, viscous, acidic</td>
</tr>
<tr>
<td></td>
<td>• Xerostomia results but is less common in children</td>
</tr>
<tr>
<td></td>
<td>• Onset within 14 hours of cancer therapy</td>
</tr>
<tr>
<td>Acute Change</td>
<td>Explanatory Notes</td>
</tr>
<tr>
<td>--------------------------------------------------</td>
<td>-------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td><strong>5. Acute Ascending Sialadenitis</strong></td>
<td>• Can occur in children as a complication of xerostomia</td>
</tr>
<tr>
<td>6. Loss of Taste (Dysguesia)</td>
<td>• Onset on treatment commencement</td>
</tr>
<tr>
<td></td>
<td>• Related to xerostomia and direct damage to taste buds</td>
</tr>
<tr>
<td></td>
<td>• Sense of taste often returns with an unpleasant interim period of altered taste</td>
</tr>
<tr>
<td></td>
<td>• Important to seek advice from dietitians as (1) the sense does not always return and (2) untreated dysgeusia can affect prognosis.</td>
</tr>
<tr>
<td>7. Dysphagia</td>
<td>• As a result of mucositis and xerostomia</td>
</tr>
<tr>
<td>8. Changes in Oral Flora</td>
<td>• Due to reduced buffering action and antibacterial action of saliva</td>
</tr>
<tr>
<td></td>
<td>• Increase in cariogenic organisms within 2 weeks of cancer therapy</td>
</tr>
<tr>
<td></td>
<td>• Increased susceptibility to candidal/viral infections</td>
</tr>
<tr>
<td>Acute Change</td>
<td>Explanatory Notes</td>
</tr>
<tr>
<td>------------------------------</td>
<td>------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>9. <strong>Periodontal / Gingival Disease</strong></td>
<td>Can be exacerbated by oral flora changes, mucositis, xerostomia and immunosuppression</td>
</tr>
<tr>
<td>10. <strong>Tooth Sensitivity</strong></td>
<td>Increased risk of toothwear observed due to bruxism + xerostomia, Gingival recession may also contribute</td>
</tr>
<tr>
<td>11. <strong>Dental Pain</strong></td>
<td>Higher risk of dental decay, May also be related to leukaemic infiltration of dental pulp tissue and direct jaw infiltration</td>
</tr>
<tr>
<td>12. <strong>Trismus</strong></td>
<td>Must exclude posterior invasion of carcinoma into pterygomasseteric muscles as a cause</td>
</tr>
<tr>
<td>13. <strong>Graft Versus Host Disease</strong></td>
<td>Can occur in an acute form after bone marrow transplantation and be followed by a chronic form</td>
</tr>
</tbody>
</table>
### TABLE 3: CHRONIC CHANGES FOLLOWING THERAPY

<table>
<thead>
<tr>
<th>Chronic Change</th>
<th>Explanatory Notes</th>
<th>Radiotherapy</th>
<th>Chemotherapy</th>
<th>BMT (Chemotherapy and Total Body Irradiation)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. <strong>Progressive endarteritis</strong></td>
<td>• Occurs in irradiated bone, especially the mandible</td>
<td>• Implications for dental extractions / surgery (see management guidelines)</td>
<td>• Implications for dental extractions / surgery (see management guidelines)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Can occur in muscle and cause trismus 3-6 months post therapy</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Uncommon in children</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2. <strong>Blood Changes</strong></td>
<td>• Anaemia</td>
<td>• Implications for dental treatment</td>
<td>• Implications for dental treatment</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Neutropenia</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Thrombocytopenia</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Prolonged by maintenance chemotherapy</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3. <strong>Trismus</strong></td>
<td>• Must exclude posterior invasion of carcinoma into pterygomasseteric muscles as a cause</td>
<td>• Predominantly due to fibrosis as a direct effect of radiotherapy</td>
<td>• Predominantly due to fibrosis as a direct effect of radiotherapy</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Predominantly due to fibrosis as a direct effect of radiotherapy, but also related to endarteritis</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4. <strong>Prolonged Oral Flora Changes</strong></td>
<td>• Increase in cariogenic organisms and candida</td>
<td>• Increased susceptibility to dental caries</td>
<td>• Viral infections and candidiasis more likely</td>
<td>• Increased susceptibility to dental caries</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Candidiasis more likely especially in denture wearers</td>
<td></td>
<td>• Candidiasis more likely</td>
</tr>
</tbody>
</table>
Table 3 contd.

<table>
<thead>
<tr>
<th>Chronic Change</th>
<th>Explanatory Notes</th>
<th>Radiotherapy</th>
<th>Chemotherapy</th>
<th>BMT (Chemotherapy and Total Body Irradiation)</th>
</tr>
</thead>
</table>
| 5. Xerostomia           | • May last up to 2 years post therapy  
• It is often considered permanent although this can be subjective  
• Predisposes to dental caries | • More prolonged if parotid glands are in the irradiation field  
• Salivary output can be maintained by ipsilateral parotid sparing during radiotherapy<sup>69</sup> |                                                                              |                                                                            |                                            |
| 6. Tooth Erosion        | • Due to prolonged xerostomia, removing protective action of saliva |                                                                              |                                                                              |                                                                            |                                            |
| 7. Periodontal / Gingival Disease | • Can continue to be exacerbated by xerostomia and oral flora changes  
• Gingival recession | • Rapid progression of periodontal disease | • Maintenance chemotherapy may increase the risk | • Rapid progression of periodontal disease can occur in children |                                            |
| 8. Adrenal Suppression  | • Can occur as a result of corticosteroid therapy |                                                                              | • Can occur as a result of corticosteroid therapy |                                                                            | Can occur as a result of corticosteroid therapy |
### TABLE 4: MANAGEMENT GUIDELINES RELATIVE TO INVASIVE DENTAL PROCEDURES

<table>
<thead>
<tr>
<th>Medical Status</th>
<th>Guidelines Available</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patients with indwelling venous access lines (e.g., Hickman).</td>
<td>American Heart Association (AHA) prophylactic antibiotic recommendations: Low risk</td>
<td>There is no clear scientific proof detailing infectious risk for these lines following dental procedures.</td>
</tr>
<tr>
<td><strong>Neutrophils</strong></td>
<td><strong>Order FBC (full blood count) with differential.</strong></td>
<td></td>
</tr>
<tr>
<td>&gt;2,000/mm³</td>
<td>AHA prophylactic antibiotic recommendations: No prophylactic antibiotics.</td>
<td></td>
</tr>
<tr>
<td>1,000–2,000/mm³</td>
<td>AHA prophylactic antibiotic recommendations: Low risk.</td>
<td>Liaise with the oncologist Clinical judgment is critical. If infection is present or unclear, more aggressive antibiotic therapy may be indicated.</td>
</tr>
<tr>
<td>&lt;1,000/mm³</td>
<td>AHA prophylactic antibiotic recommendations: Amikacin 150mg/m² 1 h pre-surgery; ticarcillin 75 mg/kg IV ½ h pre-surgery. Repeat both 6 h postoperatively.</td>
<td>The antibiotic regimen suggested by AHA is not used widely in the U.K. where amoxicillin / clindamycin are more often used. Liaise with the oncologist If organisms are known or suspected, appropriate adjustments should be based on sensitivities.</td>
</tr>
<tr>
<td>Medical Status</td>
<td>Guidelines Available</td>
<td>Comments</td>
</tr>
<tr>
<td>----------------</td>
<td>----------------------</td>
<td>----------</td>
</tr>
<tr>
<td><strong>Platelets</strong></td>
<td>*</td>
<td></td>
</tr>
<tr>
<td>Order platelet count and coagulation tests.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
| >60,000/mm³ | **National Cancer Institute guidelines** ([www.cancer.gov](http://www.cancer.gov))  
No additional support needed. | Major surgery may require platelet supplementation |
| 30,000–60,000/mm³ | Platelet transfusions are optional for non-invasive treatment  
For surgical treatment (e.g., dental extractions), consider administering platelets preoperatively and 24 h later | Liaise with the oncologist  
Platelet requirements will also depend on the extent of the surgery required / need for block injections  
Utilise techniques to promote establishing and maintaining control of bleeding (i.e. sutures, pressure packs, minimise trauma). |
| <30,000/mm³ | Platelets should be transfused 1 h before procedure  
Obtain an immediate post-infusion platelet count; transfuse regularly to maintain counts >30,000–40,000/mm³ until initial healing has occurred. In some instances, platelet counts >60,000/mm³ may be required. | In addition to the above, consider using haemostatic agents (i.e., microfibrillar collagen, topical thrombin). Tranexamic acid may help stabilise nondurable clots.  
Monitor sites carefully. |

* Assumes that all other coagulation parameters are within normal limits and that platelet counts will be maintained at or above the specified level until initial stabilization/healing has occurred.
APPENDIX 1: EXAMPLE OF SEARCH STRATEGY USED FOR MUCOSITIS / PAIN

PUBMED

<table>
<thead>
<tr>
<th>SEARCH</th>
<th>SEARCH TERMS</th>
</tr>
</thead>
<tbody>
<tr>
<td>#1</td>
<td>MESH TERM STOMATITIS OR STOMATITIS [TW] OR MUCOSITIS [TW] OR OROMUCOSITIS [TW]</td>
</tr>
</tbody>
</table>
| #2     | MESH TERM RADIOTHERAPY OR RADIOTHERAPY [TW]  
MESH TERM CHEMORADIOTHERAPY OR CHEMORADIOTHERAPY [TW] OR CHEMORADIATION [TW]  
MESH TERM RADIATION OR RADIATION [TW] OR CHEMORADIOThERAPIES [TW] OR RADIOCHEMOTHERAPY [TW] OR RADIOCHEMOTHERAPIES [TW]) |
| #3     | PAIN [TW]  
OR SORENESS [TW]  
OR SORE [TW] |
APPENDIX 2: REFERRAL FOR ORAL HEALTH CARE SCREENING

N.B. Please forward to the Dental Team prior to the commencement of Cancer Therapy

Patient Name: ____________________________ Hospital no: ____________________________
D.O.B.: ____________________________ Oncology Consultant: ____________________________
Address: ____________________________ Inpatients:

______________________________ Ward / Location ________________
______________________________ Ward telephone no: ________________
______________________________ Date admitted: ________________

Telephone no: ____________________________ Duration of stay:

<table>
<thead>
<tr>
<th>Diagnosis:</th>
<th>1.</th>
<th>2.</th>
<th>3.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Past Medical History:</td>
<td>1.</td>
<td>2.</td>
<td>4.</td>
</tr>
<tr>
<td></td>
<td>3.</td>
<td>4.</td>
<td>5.</td>
</tr>
<tr>
<td></td>
<td>5.</td>
<td>6.</td>
<td>6.</td>
</tr>
<tr>
<td>Current Medication:</td>
<td>1.</td>
<td>4.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>2.</td>
<td>5.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>3.</td>
<td>6.</td>
<td></td>
</tr>
<tr>
<td>Treatment to date: (including radiotherapy dose, mask and chemotherapy regime)</td>
<td>1.</td>
<td>2.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>3.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Treatment proposed with dates: (including radiotherapy dose, mask and chemotherapy regime)</td>
<td>1.</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>2.</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>3.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Tick as appropriate:

☐ URGENT (Contact Dental Team by phone) ☐ ROUTINE

Name of referrer ____________________________ Date ____________________________
Signature ____________________________ Contact number ____________________________
Position ____________________________
# APPENDIX 3: PRACTICAL ORAL CARE:

Care of the edentulous patient should start at step 5.

<table>
<thead>
<tr>
<th>Oral Care</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>1. Tooth brushing</strong></td>
<td>• Use a medium brush if possible, soft one if too sore&lt;br&gt;• Encourage or assist with gentle thorough brushing of teeth and gums at least twice daily&lt;br&gt;• Use a high fluoride toothpaste&lt;br&gt;• Spit out excess, do not rinse&lt;br&gt;• If toothbrushing has to be discontinued it should be resumed at the earliest opportunity&lt;br&gt;• Patients at risk of aspiration should have suction available and sit up</td>
</tr>
<tr>
<td><strong>2. Aqueous alcohol free chlorhexidine gluconate mouthwash</strong></td>
<td>• Recommended for short term use if tooth brushing is inadequate&lt;br&gt;• If toothbrushing is discontinued, use three to four times daily&lt;br&gt;• Thirty minutes should be allowed between use of chlorhexidine and tooth brushing&lt;br&gt;• Mouthwashes may need to be diluted for comfort, i.e. 10ml mouthwash to 10ml water, ensuring the whole diluted volume is used&lt;br&gt;• N.B. Stagger use of chlorhexidine mouthwash and nystatin antifungal agent - separate administration by at least one hour.</td>
</tr>
<tr>
<td><strong>3. Fluoride mouthwash</strong></td>
<td>• Fluoride should be used both during and after cancer therapy&lt;br&gt;• Use a high fluoride toothpaste when tooth brushing&lt;br&gt;• Use an alcohol free fluoride mouthwash daily as directed by the dental team&lt;br&gt;• Fluoride gel / varnish may be used, as directed by the dental team. Fluoride varnish or gel should not be used during acute episodes of mucositis</td>
</tr>
<tr>
<td><strong>4. Pain relief mouthwashes / sprays</strong></td>
<td>• Benzydamine HCL mouthwash / spray may be of benefit if there is mucosal discomfort due to mucositis</td>
</tr>
<tr>
<td><strong>5. Dietary advice</strong></td>
<td>• Preventive advice to reduce the risk of dental decay should be given in liaison with a dietitian.&lt;br&gt;• Emphasis should be placed on adequate hydration and assist with healthy meal choices</td>
</tr>
</tbody>
</table>
### Oral Care

<table>
<thead>
<tr>
<th>Oral Care</th>
<th>Notes</th>
</tr>
</thead>
</table>
| 6. Gentle Swabbing of the Oral Tissues | Where available, polygon/gauze swabs soaked in alcohol free chlorhexidine mouthwash may be used to gently clean the oral tissues  
If the above cannot be tolerated, the swabs may be soaked in 0.9% saline (N.B. no antibacterial effect) |
| 7. Moisten mouth and lips frequently |  
Advise regular sips of water  
Oral Balance or similar gel may be applied to dry lips or mucosa, this can be particularly helpful at night  
Use recommended artificial saliva substitutes |
| 7. Swabs for candidal superinfection |  
Regular swabs should be taken for detection of candida  
Topical / systemic antifungal agents should be prescribed following the diagnosis of candida |
| 8. Care of appliances |  
After each meal / at least twice daily, dentures and obturators should be removed and meticulously cleaned with a tooth or denture brush  
It is advisable to do this over a basin of water to prevent damage if the appliance is dropped  
Rinse well before replacing in cleaned mouth  
Antifungal agents, as prescribed may be applied to the fit surface of the denture prior to re-insertion  
Remove all dentures at night and clean; soak in chlorhexidine mouthwash overnight. An alternative is dilute sodium hypochlorite solution (Milton’s diluted 1 in 80) provided there are no metal components  
If stored away from the patient they should be appropriately labelled |
| 9. Appliance wear |  
Removable prostheses should be left out of the mouth if there is any evidence of ulceration  
Dentures should be removed at night  
Denture should be moistened with water or an appropriate saliva substitute before reinsertion  
Obturators should not be left out at night for the first 6 months. A specialist opinion should be sought if there is evidence of ulceration |
APPENDIX 4: ORAL ASSESSMENT GUIDE

Please insert appointment number in relevant box based on your clinical examination of the patient.
Contact the Dental Team for further advice on the management of patients with scores of 3.

<table>
<thead>
<tr>
<th>PATIENT NAME: ________________</th>
<th>METHOD OF ASSESSMENT</th>
<th>DATE AND SIGNATURE</th>
</tr>
</thead>
<tbody>
<tr>
<td>ASSESSMENT</td>
<td></td>
<td>1  2  3  4  5  6  7  8</td>
</tr>
<tr>
<td>VOICE</td>
<td>Converse with the patient. Listen to speech</td>
<td></td>
</tr>
<tr>
<td>3 = Difficult/ painful speech</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2 = Deeper/ raspy</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1 = Normal</td>
<td></td>
<td></td>
</tr>
<tr>
<td>SWALLOW</td>
<td>Ask patient to swallow</td>
<td></td>
</tr>
<tr>
<td>3 = Unable to swallow</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2 = Painful</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1 = Normal</td>
<td></td>
<td></td>
</tr>
<tr>
<td>LIPS AND ANGLE OF MOUTH</td>
<td>Observe and palpate the tissues</td>
<td></td>
</tr>
<tr>
<td>3 = Ulcerated / with or without bleeding</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2 = Dry / cracked</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1 = Normal</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
## APPENDIX 4: ORAL ASSESSMENT GUIDE CONT'D.

<table>
<thead>
<tr>
<th>ASSESSMENT</th>
<th>METHOD OF ASSESSMENT</th>
<th>1</th>
<th>2</th>
<th>3</th>
<th>4</th>
<th>5</th>
<th>6</th>
<th>7</th>
<th>8</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>TONGUE</strong></td>
<td>Observe the appearance of the tissues</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3 = Blistered / cracked</td>
<td>Observe the appearance of the tissues</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2 = Coated or loss of papillae</td>
<td>Observe the appearance of the tissues</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1 = Smooth, pink, moist</td>
<td>Observe the appearance of the tissues</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>SALIVA</strong></td>
<td>Insert tongue depressor and observe tongue, floor of mouth</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3 = Absent</td>
<td>Insert tongue depressor and observe tongue, floor of mouth</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2 = Thick / ropy</td>
<td>Insert tongue depressor and observe tongue, floor of mouth</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1 = Watery</td>
<td>Insert tongue depressor and observe tongue, floor of mouth</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>MUCOUS MEMBRANES/GINGIVA</strong></td>
<td>Observe the appearance of the tissues</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3 = Ulceration / bleeding - gentle pressure</td>
<td>Observe the appearance of the tissues</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2 = Candidal infection suspected - reddened/coated or white patches</td>
<td>Observe the appearance of the tissues</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1 = Pink and moist</td>
<td>Observe the appearance of the tissues</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>ORAL CLEANSING COMPLIANCE</strong></td>
<td>Observe tooth brushing / denture cleaning</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3 = Unable to clean</td>
<td>Observe tooth brushing / denture cleaning</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2 = Cleans but needs help</td>
<td>Observe tooth brushing / denture cleaning</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1 = No difficulties</td>
<td>Observe tooth brushing / denture cleaning</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Taking Care of Your Mouth during Radiotherapy or Chemotherapy

This leaflet gives you information on how to manage the possible side effects in the mouth due to radiotherapy and chemotherapy

Key points
- Radiotherapy and chemotherapy are treatments that are used to treat cancer.
- Radiotherapy to the head and neck and chemotherapy can cause side effects in the mouth.
- Your mouth needs to be as healthy as possible before the start of treatment to avoid problems later.
- Infected teeth and gums can be a risk during cancer treatment.
- You should have a thorough dental check-up and seek advice from a dentist before cancer treatment starts.
- If you have cancer of the head and neck, this is arranged by the oncology team when they plan your care.
- For other patients receiving cancer therapy, let your oncology team know if you don’t have a dentist – they may be able to arrange an appointment for you.
- Throughout your radiotherapy or chemotherapy your mouth needs careful monitoring by either a dental hygienist or an appropriately trained nurse.

How can my mouth be affected by cancer treatment?
- Not everyone will get changes in the mouth during cancer treatment
- About two weeks after the start of radiotherapy and chemotherapy you may notice changes
- The most common side effects include general soreness and mouth ulcers, dry mouth, altered / loss of taste and difficulty swallowing and eating.
- These generally improve a couple of weeks after cancer treatment is completed.

How can I help to reduce the impact of chemotherapy and radiotherapy on my mouth?
- Brush teeth twice daily using toothpaste, which contains fluoride to prevent dental decay.
- Keep dentures clean and take them out at night.
- Sugary snacks and drinks can cause dental decay – the dietician may need you to have these to keep your energy up. Discuss with the dentist how you can try and protect your teeth.
- Use a pain relieving mouthwash if your mouth is sore (ask you dentist / doctor for advice).
- Sip water if your mouth is dry – avoid sipping sugary or acidic drinks or sucking sweets.

What else should I do?
- Stop smoking – you can ask your doctor for help with this.
- Reduce alcohol consumption.
- Attend your dentist regularly and tell them about any problems that you are experiencing.
- Lifelong dental care is recommended
<table>
<thead>
<tr>
<th>Possible side effect of treatment</th>
<th>Why does this happen during your cancer therapy?</th>
<th>What can I do?</th>
<th>What should I avoid?</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sore mouth</td>
<td>Radiotherapy and chemotherapy can make the lining of your mouth thin. This can make your mouth, tongue and throat may become red and sore. You may also get mouth ulcers. It can become uncomfortable to eat, speak, swallow and brush your teeth.</td>
<td>✓ Your dentist or doctor can recommend / give you a mouthwash to help with the soreness. If there is thrush in your mouth, they can give you medication for this. Use a brush with a small head to clean your teeth with a fluoride toothpaste. If your blood counts are very low, a soft brush may be used for a limited period of time.</td>
<td>✓ Strongly flavoured toothpaste or mouthwash.</td>
</tr>
<tr>
<td>Dry Mouth</td>
<td>Radiotherapy can damage the glands which produce saliva. Saliva moistens the mouth and protects against tooth decay and tooth sensitivity. The dryness is worse during treatment but slowly improves. Saliva may not return completely.</td>
<td>✓ Sip water frequently. Try and chew sugar-free gum. Discuss saliva substitutes with the dentist / doctor. Oral gel or lubricant (e.g. Vaseline, Cetraben) are useful to coat and protect the lips and soft tissues. Follow the dietitian’s advice regarding food and drink.</td>
<td>✓ Fizzy drinks, diet drinks and fruit juice. Sucking / chewing sweets</td>
</tr>
<tr>
<td>Altered / Loss of taste</td>
<td>Radiotherapy and chemotherapy can affect your taste buds. A dry mouth can also affect your taste. Taste will return after cancer treatment is completed.</td>
<td>✓ Sip water regularly.</td>
<td>✓ Fizzy drinks, diet drinks and fruit juice. Sucking / chewing sweets.</td>
</tr>
<tr>
<td>Possible side effect of treatment</td>
<td>Why does this happen during your cancer therapy?</td>
<td>What can I do?</td>
<td>What should I avoid?</td>
</tr>
<tr>
<td>-----------------------------------</td>
<td>-------------------------------------------------</td>
<td>----------------</td>
<td>-------------------</td>
</tr>
</tbody>
</table>
| Difficulty swallowing / eating    | • Dryness and soreness of the mouth makes swallowing difficult  
• This can reduce your enthusiasm for food and contribute to weight loss | ✓ Let your oncology team know if this occurs as they can monitor this and help  
✓ Rinse your mouth with a pain relieving mouth wash before eating (the dentist / doctor can give you this)  
✓ Sip water frequently  
✓ Eat moist food / have water with food  
✓ Eat high energy food such as pasta, bread, and potatoes  
✓ Speak with your oncology team who can arrange for you to see a dietitian if you are losing weight | ✓ Hard / dry food  
✓ Acidic food |
| Difficulty Wearing Dentures       | • Lack of saliva and mouth soreness can make dentures difficult to wear. | ✓ See your dentist if your dentures are painful  
✓ Clean your dentures after each meal, at least twice daily | ✓ Do not sleep with your dentures in your mouth |

Useful Contacts for Additional Support
1. **The Mouth Cancer Foundation**, C/O Media Ambitions (Enterprises) Limited, 1 Victoria Parade, Sandycombe Road, Kew, Surrey, TW9 3NB, Phone: 02089402222, Email: info@mediaambitions.com
2. **Changing Faces**, The Squire Centre, 33-37 University Street, London WC1E 6JN, info@changingfaces.org.uk
4. **BACP**: British Association of Counselling and Psychotherapy, 15 St John’s Business Park, Lutterworth, LE17 4HB
5. **Let’s Face It**, 1 Victoria Place, 90 Westgate Bay Avenue, Westgate on Sea, CT8 8NG, Tel: 01843491291
6. **Maggie’s Centres**, https://www.maggiescentres.org/; Tel: 0300 123 1801